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Summary
AU-rich element (ARE)-mediated mRNA decay (AMD) is a prominent mode
of mRNA degradation considering 10-15 % of mRNAs in the cell contain AREs
in their 3’ untranslated region (UTR). AMD is majorly promoted by the Tris-
tetraproline (TTP) family of proteins which bear extensive homology among
each other. This family comprises TTP and Butyrate response factors (BRF)
1 and 2. These proteins bind to AREs in mRNA 3’UTRs and accelerate degra-
dation of these mRNAs. In my study, I characterized the protein BFR2 and
tried to determine its possible role in AMD. Results suggested that BRF2 de-
grades mRNAs in an ARE-dependent manner and that BRF2 binds to 14-3-3
protein in a phosphorylation-dependent manner. I performed a detailed inter-
action analysis of BRF2 with 14-3-3 as a possible means of AMD-regulation by
BRF2. I could establish that the serine residues S123 and S257 in BRF2 are
the binding sites for 14-3-3 and that simultaneous mutation of both sites was
neccessary to abolish 14-3-3 binding. The kinase MK2 appeared to affect the
BRF2-14-3-3 interaction. However, unlike observed for TTP and BRF1, over-
expression of MK2 did not reduce AMD efficiency of BRF2. This could possibly
imply that BRF2 is resistant to inactivation by stress-induced kinases. 14-3-3
binding mutants of BRF2 localized slightly more nuclear than BRF2 wild-
type which was predominantly cytoplasmic. Upon arsenite stress, a fraction of
nuclear wildtype BRF2 seemed to relocalize to the cytoplasm. All 14-3-3 bind-
ing mutants equally efficiently localized to processing bodies and to oxidative
stress-induced stress granules with slightly different efficiencies. Preliminary
co-immunoprecipitation experiments suggested an interaction between BRF2
and the mRNA deadenylation machinery. The fragments BRF2:aa1-275 (N-
terminus + RNA binding region) and BRF2:aa97-275 (RNA binding region)
both localized to the nucleus. This could be due to the absence of the nuclear
export signal (NES) from the C-terminus. Interestingly, upon oxidative stress,
BRF2:aa1-275 shifted to the cytoplasm, which hinted to the presence of an
additional N-terminal NES that is active upon oxidative stress. In addition,
the central RNA binding domain consisting of the two 14-3-3 binding sites
and two zinc fingers appeared to be sufficient to cause AMD of ß-globin-ARE
reporter mRNAs. However, despite being predominantly nuclear, the frag-
ments BRF2:aa1-275 and BRF2:aa97-275 still promoted AMD. This opens up
an interesting idea as to whether AMD could be nucleus-associated.
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Zusammenfassung
Durch AU-reiche Elemente (ARE) vermittelter mRNA Abbau (AMD) ist eine
bedeutende Form des mRNA Abbaus in der Zelle, da 10-15 % aller mRNAs
ein ARE in ihrer 3’ untranslatierten Region (UTR) beinhalten. Diese mR-
NAs kodieren für Proteine, die an wichtigen zellulären Prozessen beteiligt
sind, beispielsweise Zellwachstum und -erhaltung, Entwicklung, Transkription,
Entzündung oder Apoptose. AMD wird hauptsächlich von Proteinen der Tris-
tetraprolin (TTP) Familie, bestehend aus TTP, BRF1 und BRF2 vermittelt,
die mRNA Abbau durch Bindung an AREs in der 3’UTR beschleunigen. Trotz
ihrer beträchtlichen Homologie zeigen die Proteine der TTP Familie unter-
schiedliche Eigenschaften. In meiner Doktorarbeit habe ich das Protein BRF2
charakterisiert und seine mögliche Funktion in AMD bestimmt. Meine Ex-
perimente deuten darauf hin, dass der mRNA Abbau durch BRF2 von AREs
abhängt, und dass BRF2 abhängig von seinem Phosphorylierungsstatus an 14-
3-3 bindet. Die Interaktion von BRF2 und 14-3-3 habe ich als eine mögliche
Form der Regulation der AMD-Aktivität von BRF2 genauer untersucht. Ich
konnte zeigen, dass 14-3-3 über die Bindestellen Serin123 und Serin257 an
BRF2 bindet, und dass es notwendig ist, beide Serine zu mutieren, um diese
Interaktion zu verhindern. Die Kinase MK2 scheint die Phosphorylierung von
BRF2 und damit die Bindung an 14-3-3 zu beeinflussen, da diese Interak-
tion in Anwesenheit einer inaktiven Form von MK2 reduziert ist. Anders
als für TTP und BRF1 scheint MK2 die AMD-Effizienz von BRF2 nicht zu
beeinträchtigen. Dies könnte darauf hinweisen, dass BRF2 resistent gegenüber
der Inaktivierung durch Stress-induzierte Kinasen ist. 14-3-3 Bindungsmu-
tanten von BRF2 zeigen verglichen mit dem vorwiegend zytoplasmatischen
BRF2 Wildtyp eine stärkere Kernlokalisation. Nukleäres BRF2 verlagert sich
durch Arsenit-Stress teilweise ins Zytoplasma. Alle 14-3-3 Bindungsmutan-
ten lokalisieren mit gleicher Effizienz in processing bodies und zeigen leicht
unterschiedliche Lokalisation in Arsenit-induzierten stress granules. Erste Co-
Immunopräzipitationen weisen auf eine Interaktion zwischen BRF2 und der
mRNA Deadenylierungs-Maschinerie hin. Die Fragmente BRF2:aa1-275 (N-
Terminus + RNA-Bindungsregion) und BRF2:aa97-275 (RNA Bindungsre-
gion) zeigen beide Kernlokalisation. Ein Grund dafür könnte das fehlende
nukleäre Exportsignal (NES) am C-Terminus sein. Interessanterweise ver-
schiebt sich BRF2:aa1-275 unter oxidativem Stress ins Zytoplasma, was auf
ein weiteres N-terminales NES hinweist, welches unter oxidativem Stress aktiv
ist. Außerdem scheint die zentrale RNA-Bindedomäne, die aus den zwei 14-3-3
Bindestellen und zwei Zinkfingern besteht, ausreichend zu sein, um AMD von
ARE-Reporter mRNAs zu bewirken. Obwohl mBRF2:aa97-275 hauptsächlich
nukleär vorkommt, löst die Mutante immer noch AMD aus. Dies eröffnet das
neue interessante Konzept, dass AMD Kern-assoziiert sein könnte.
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1 Introduction
The central dogma of molecular biology indicates that genetic information
flows from DNA to RNA to proteins. DNA can be present in the active form,
euchromatin; or the inactive form, heterochromatin. RNA can be controlled at
the level of transcription, localization, storage, or translation. Lastly, proteins
could be controlled at the levels of expression, activity, stability, or localization.
All the above modes of regulation are to ensure that the final product, proteins,
are expressed in a timely manner and only in the exact quantities required.
Considering the scope of my project, I will briefly explain the process of mRNA
degradation and thereforth focus on adenylate/uridylate-rich element (ARE)-
mediated mRNA decay.
1.1 Control of mRNA levels in the cell
In complex eukaryotes, a majority of DNA is transcribed; however, only a frac-
tion of these transcripts get translated [1, 2]. mRNA gets transcribed in the
nucleus. Subsequently, it is exported to the cytoplasm where it faces different
fates depending on what protein complex loads onto it. These fates can be
broadly categorized as: translation, translational suppression till the mRNA
attains a desired localization in the cell, or deadenylation followed by stor-
age/degradation. Controlling levels of mRNA is an efficient way of controlling
the proteome. The range of stability of mRNAs varies greatly; the half-lives
ranging from 20 mins for labile mRNAs to more than 24 hrs for some stable
mRNAs [3]. Short-lived mRNAs can elicit temporary but potent responses to
different stimulii like growth, inflammation, oxidative or nutrient deprivation
stress, etc. Moreover, the cell has evolved pathways to eliminate aberrantly
processed mRNAs or mRNAs originating from mutated genes. Taken together,
the half-life of each mRNA is decided based on its quality and its function after
which it is destined to undergo degradation. There exist multiple surveillance
mechanisms where damaged mRNAs are rapidly scavenged, namely, Nonsense-
mediated decay (NMD) where the transcripts harbour a premature stop codon
(PTC), Nonstop mRNA decay (NSD) where transcripts lacking a stop codon
are degraded, No-go mRNA decay (NGD) where mRNAs with stalled transla-
tion elongation are degraded (reviewed in [4]). An additional type of mRNA
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decay is ARE-mediated RNA decay (AMD) where factors bind to specific cis-
acting elements in the 3’UTR of mRNA and thus target it for degradation.
Though the pathways targeting the mRNAs for degradation are diverse, all
the above pathways converge after the mRNA recognition step and thereforth
follow similar steps towards degradation, i.e., deadenylation, decapping, and
endo/exoribonuclease digestion of the mRNA body. Eukaryotic mRNAs bear
modifications at the 5’ and the 3’ end, and proteins binding to these structures
offer protection to the mRNA body and render it inaccessible to exonucleases.
Therefore, once an mRNA is destined for degradation, the initial steps involve
removal of these modifications to prepare the mRNA body for the ribonuclease
action. The following is a concise description of the important steps common
to most degradation pathways of mRNA degradation.
1.2 Degradation of mRNA
1.2.0.1 Deadenylation
The polyA tail interacts with polyA binding protein (PABP) present in the
cytoplasm. This interaction supports translation and protects the mRNA from
a 3’-5’ exoribonuclease activity [5]. The process of deadenylation involves pro-
gressive shortening of the polyA tail. However, after successful deadenylation,
the mRNA can revert back to getting re-adenylated and can enter active trans-
lation. Hence, deadenylation is a fairly reversible process [6, 7]. There are three
main deadenylases in present in eukaryotic cells; the polyA-specific ribonucle-
ase (PARN), the polyA nuclease 2 (PAN2)-PAN3 deadenylase complex, and
the Ccr-Caf1-Not deadenylation complex.
The polyA ribonuclease (PARN): belongs to the DEDD (Asp-Glu-Asp-Asp mo-
tif) family of nucleases. It is a nucleo-cytoplasmic shuttling protein although
mainly localized to the nucleus [8]. It requires Mg+2and a free 3’ hydroxyl
group for action and releases solely 5’-AMP [9]. Although known for dead-
enylating polyA tails, it has also been shown to degrade polyU tails at a
~10-fold lower efficiency [10]. Since polyU tails are majorly found in oocytes
[11], this finding might support the role of PARN in embryogenesis [12]. The
cap binding protein 80 (CBP80) binds to PARN inhibiting it from deadenylat-
ing nascent pre-mRNA [13] in untreated conditions. Moreover, in conditions
of DNA damage where deadenylation is transiently but strongly inhibited, the
cleavage stimulation factor 1 (CstF1) interactes with PARN inhibiting its ac-
tivity [14]. Nuclear PARN decreases the stability of ARE-containing mRNAs,
such as c-myc, c-fos, and c-jun, keeping their levels low in non-stress conditions
[14, 15, 16]. The levels of these mRNAs therefore increase transiently due to
an inactive PARN in UV-induced DNA damage conditions [17, 18, 19].
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The PAN2-PAN3 deadenylation complex: PAN2 and PAN3 are active as a het-
erodimer where PAN2 is catalytic and PAN3 is the regulatory subunit. This
deadelylase complex is majorly cytoplasmic, requires a free 3’ hydroxyl group
for action, and releases 5’-AMP as the product. PAN is activated on inter-
action with PABP, unlike for PARN and the Ccr4-Caf1-Not complex which
are inhibited by PABP [20, 21, 22]. In higher eukaryotes, PAN is the first in
line to act on polyA tails, reducing them to a length of ~100 nt from 200-250
nt, thus performing only incomplete deadenylation [22]. This implies that a
second deadenylase follows the activity of PAN and takes the deadenylation
to completion [8]. PAN complex is known to be regulated by ARE sequences
in the 3’ untranslated region (UTR) of mRNAs [22].
The Ccr4-Caf1-Not complex: Along with PAN, the Ccr4-Caf1-Not complex is
responsible for cytoplasmic mRNA deadenylation, although unlike PAN, the
Ccr4 exoribonuclease in the Ccr4-Caf1-Not complex is inhibited by PABP [8].
In its function, the Ccr4-Caf1-Not complex further deadenylates the mRNAs
which are partially deadenylated by PAN and reduces the polyA tails from
~100 nt to ~8-12 nt [5]. Collart et al. [23] have reviewed the components of
the Ccr4-Caf1-Not complex in detail. The complete complex is ~1.9 MDa in
size [24] and consists of the Not 1-4 and Not10, Ccr4a/b, Caf1a/b, TAB182,
and C2ORF29. Not1 was suggested to act as a platform onto which the other
components of the complex load. Ccr4 is a 3’ to 5’ exoribonuclease, the activity
of which depends on the length of the polyA tail. It interacts with Not1 via
Caf1, which is also an exoribonucease. Similar to Ccr4, the activity of Caf1 is
dependent on the length of the polyA tails [25].
1.2.0.2 Decapping
Decapping is a process by which the 5’ m7G cap is removed from the mRNA
body thus making the mRNA body accessible to exoribonucleases. Unlike
deadenylation, decapping is an irreversible process [26]. The decapping com-
plex consists of the Dcp1 and Dcp2 proteins, of which Dcp2 exhibits the de-
capping activity while Dcp1 acts as an enhancer of Dcp2 activity [27]. Dcp2
activity requires the 7-methyl group on the cap and the 5’ body of the mRNA.
Incidentally, phosphorylation of Dcp1 and Dcp2 governs efficiency of P body
and stress granule formation [28, 29].
1.2.0.3 Degradation of the mRNA body:
Xrn1 exoribonuclease: is a ~175 kDa enzyme which is highly specific for mR-
NAs bearing 5’ monophosphate generated by the decapping action of Dcp1/2
[30, 31, 32] and cleaves mRNA in a 5’ to 3’ direction. Xrn1 is also involved in
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degrading endonucleolytic mRNA cleavage products from the NMD and NGD
mRNA degradation pathways [33, 34, 35, 36] or 5’ monophosphorylated mR-
NAs generated by Argonaute-catalysed endonucleolytic cleavage during RNA
interference [37, 38, 39].
Exosome: is a 12-subunit complex which contributes to 3’ to 5’ exoribonucle-
olytic activity. The exosome has been implicated in the AMD [40, 41] and the
NMD pathways [42].
A list of proteins involved in mRNA degradation has been included below.
Table 1.1: Proteins involved in mRNA decay
Protein Domains Function
Localizat-
ion
Refs
Deadenylation
Pan2
DEDD
(3’- 5’ Exo)
initial deadenylation,
distributive, activated by
PABP1
C, PB [8, 43]
Pan3 - co-factor of Pan2 C, PB [43]
Ccr4
Exo III
(3’- 5’ Exo)
terminal deadenylation,
processive, inhibited by
PABP1
N, C, PB
[8, 44, 45,
46]
Caf1,
Pop2
Exo III
(3’- 5’ Exo)
terminal deadenylation,
processive, inhibited by
PABP1
N, C, PB
[43, 44,
46, 25,
47]
Not1 -
scaffold of the Ccr4-Caf1-Not
complex
N, C, PB [47, 48]
Not2 - n.d. N, C, PB [47, 48]
Not3 - n.d. N, C, PB [47, 48]
Not4
RING
finger
E3 ligase N, C, PB [48, 49]
Tob2
interacts with Caf1, enhances
deadenylation
C, PB [50]
PARN
DEDD
(3’- 5’ Exo)
Nuclear in somatic cells,
cyto-plasmic in oocytes,
embryonal development
N, C [51]
Nocturnin
Exo III
(3’- 5’ Exo)
circadian expression C [47, 52]
Decapping
Dcp2 Nudix decapping enzyme C, PB
[53, 54,
55, 56]
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Table 1.1: Proteins involved in mRNA decay
Protein Domains Function
Localizat-
ion
Refs
Dcp1 - enhancer of decapping C, PB
[54, 55,
56]
Rck,
Dhh1
DEAD
helicase
RNA helicase, enhancer of
decapping
C, PB
[45, 56,
57, 58,
59]
Edc3,
Lsm16
-
enhancer of decapping, PB
aggregation
C, PB [60, 61]
Edc4,
Hedls,
Ge-1
- enhancer of decapping C, PB [60, 62]
Lsm1-7 Sm
binds mRNAs with short
poly(A) tails, enhancer of
decapping
C, PB
[63, 45,
56, 61,
64, 54]
Pat1 -
connects deadenylaiton with
decapping, enhancer of
decapping, PB aggregation
C, PB
[65, 66,
67, 68]
Ro52
enhancer of decapping, E3
ligase
C, PB [69]
Nudt16 Nudix decapping enzyme C [70, 71]
5’-3’ Decay
Xrn1
5’-3’ ex-
onulcease
5’-3’ exonulcease C, PB [72, 73]
Xrn2
5’-3’ ex-
onulcease
5’-3’ exonulcease N [74, 75]
3’-5’ Decay
Rrp44,
Dis3,
EX-
OSC11
RNase II,
S1, PIN
endonucle-
ase
active 3’-5’ exonulcease and
endonuclease of the exosome
N
[76, 77,
78]
Dis3L1 C [79]
Rrp6,
PmScl-
100,
EX-
OSC10
DEDD
(3’- 5’ Exo)
3’-5’ exonulcease N, C
[40, 80,
42]
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Table 1.1: Proteins involved in mRNA decay
Protein Domains Function
Localizat-
ion
Refs
Rrp41,
Ski6,
EXOSC4
RNase PH
(inactive)
exosome core N, C
[40, 78,
80]
Rrp42,
EXOSC7
RNase PH
(inactive)
exosome core N, C [78, 80]
Rrp43,
Oip2,
EXOSC8
RNase PH
(inactive)
exosome core N, C [40, 78]
Rrp45,
PmScl-
75,
EXOSC9
RNase PH
(inactive)
exosome core N, C [40]
Rrp46,
EXOSC5
RNase PH
(inactive)
exosome core N, C [40, 80]
Mtr3,
EXOSC6
RNase PH
(inactive)
exosome core N, C [40, 80]
Rrp4,
EXOSC2
KH, S1 RNA binding N, C
[40, 78,
80]
Rrp40,
EXOSC3
KH, S1 RNA binding N, C [40, 80]
Csl4,
EXOSC1
S1 RNA binding N, C [40, 80]
Endonucleolytic cleavage
Ago2 RNase H
cleavage of siRNA-mRNA
duplex
C, PB,
SG
[81, 82,
83, 84,
85]
Smg6
PIN en-
donuclease
cleavage of NMD targets C, PB
[35, 34,
86]
Zc3h12a
PIN en-
donuclease
cleavage of IL-6 and IL-12b
mRNA within stem-loop
C [87]
1.3 Cytoplasmic RNA granules:
Cytoplasmic granules containing RNA are a common feature in plants, yeast,
and mammalian cells. Processing bodies and stress granules are examples
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of such structures and are suggested to offer a site for temporary storage of
mRNAs and/or mRNA degradation. These granules are formed as a byprod-
uct of mRNA metabolism or in response to stress-inducing cues. Both these
structures exist independently but have an overlapping set of components [88].
1.3.1 Processing bodies:
Processing bodies (P bodies): are small cytoplasmic foci that include proteins
required for mRNA degradation. Though the concept of P bodies was con-
solidated a lot later, XrnI exoribonuclease was first shown to have a punctate
cytoplasmic localization [72]. Studies in the years later revealed many other
mRNA degradation-related proteins to be a part of P bodies. These proteins
have roles that span all the important steps in mRNA degradation, namely,
deadenylation, decapping, and final degradation of the mRNA body. The
arguement that mRNA degradation takes place in P bodies has been strength-
ened by the following observations. It has been shown that P bodies fail to
form on inhibition of deadenylation. Ccr4 and Caf1 proteins which play a
prominent role in deadenylation appear essential for the formation of P bod-
ies, since knockdown of these proteins led to failure of P-body formation. On
the other hand, P bodies show an increased size when 5’ to 3’ mRNA degrada-
tion is blocked by knockdown of XrnI. In these cases the mRNA destined for
degradation or the decay intermediates accumulate inside P bodies [56, 45].
Blocking decapping produced the same effect [56]. The exosome components
have, to date, not been observed in P bodies.
Function: P bodies have been linked with the degradation of many short-lived
mRNAs. These mRNAs comprise those with premature termination codons
(PTCs) degraded by the NMD pathway, those with AREs in their 3’UTR
degraded by the AMD pathway, and those mRNAs which undergo microRNA
(miRNA)-induced silencing. This is supported by the fact that some proteins
prominently involved in these pathways localize to P bodies; NMD: Upf1-
3, Smg5-7 [89, 86, 90]; AMD: Tristetraprolin family members, HuD [63, 91,
92]; and miRNA-induced mRNA silencing: Ago1-4, GW182 [81, 82, 93, 94].
Proteins involved in AMD and miRNA-induced silencing pathways localize
more or less readily to P bodies. However, a study has indicated that P bodies
were not required for NMD [95]. Localization of mRNAs to P bodies was
reversible and these mRNAs held the potential to re-enter translation. This
was shown in S. cerevisiae where disassembly of P bodies on stress recovery
corresponded to re-entry into translation [96]. This assigns an mRNA-storage
function to P bodies.
Assembly and dissasembly: Studies in S. cerevisiae [61] and C. albicans [97]
provided evidence that P body assembly is greatly governed by the enhancer
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of decapping 3 (Edc3) protein. Edc3 interacts with itself, and with Dcp2 and
Rck to form a scaffold. Another contributing protein with a similar function
is Pat1 which networks multiple P body proteins [98, 65, 67]. Lsm4 was im-
plicated in the assembly of P bodies and was suggested to form aggregates
by virtue of a Q/N (glutamine and asparagine)-rich domain present in its C
terminus [61]. Such a domain was later found to be a feature of many P body
proteins [99]. Stimulii determining assembly and disassembly of P bodies have
hitherto been poorly understood, although some studies describe the cues in-
volved. P body dynamics appear to be closely related to the stages of growth.
Stationary phase S. cerevisiae cells were observed to have large P bodies that
stored mRNAs till growth resumed [96]. In C. albicans, P bodies were observed
during hyphal developent and an edc3 deletion mutant exhibited a dramatic
reduction of P bodies accompanied by defective filamentation [97]. Recent re-
ports demonstrate that phosphorylation of the S315 on Dcp1a by the kinase
JNK led to reduced number of P bodies in mammalian cells and that localiza-
tion of XrnI and Edc4 was determined by Dcp1a. Prolonged JNK activation
led to dispersal of P bodies [28]. Phosphorylation of Dcp2 on S137 by Ste20
kinase, affected its decapping activity, triggered accumulation of this Dcp2 in
processing bodies, and promoted efficient formation of stress granules in S.
cerevisiae. Ste20 kinase activates mitogen-activated protein kinase (MAPK)
cascades [29]. Poliovirus infection elicited degradation of XrnI, Dcp1a, and
Pan3, and eventually disrupted P bodies in these cells correlating with expres-
sion of viral proteases [100]. Intact microtubules were required for motility of
P bodies and drug-induced disruption of microtubules led to an increase in the
number of P bodies [101].
1.3.2 Stress granules:
Stress granules (SGs): are cytoplasmic mRNP complexes which form when
translation initiation is impaired. Hindered translation initiation could be
attributed to reasons like stress-induced reduction in translation initiation,
drug-based prevention of translation initiation, knockdown of initiation factors,
or over-expression of proteins that inhibit translation (reviewed in [88]).
Function: SGs are implicated in translational repression [102], protecting mR-
NAs from deadenylation during stress responses [103, 104, 105], possibly ac-
cumulating components in SGs to reduce the components in cytosol [88], and
increasing the local concentration of components to possibly accelerate mRNP
assembly on stress recovery [88]. It is a plausible idea that on stress recovery
the initiation complex loads onto the mRNA while inside the SGs, although
translation might not be initiated due to the lack of 60S ribosomal subunit
[106, 88]. This model could also explain presence of proteins like DDx3, Pbp1,
10
Introduction
HuR, Lin28 [107], and proteins which promote translation from internal ri-
bosomal entry sites (IRES) sequences being present in SGs. These proteins
promote stress-tolerant translation of specific mRNAs [108, 109, 110, 111].
SGs seem to play a role in sequestering pro-apoptotic proteins, so as to mini-
mize their activity in modest stress conditions from which recovery is possible.
RACK1 interacts with MTK1 kinase thus activating it leading to induction
of apoptosis. Sequestering RACK1 in SGs prohibits this interaction and thus
activation of apoptosis, Similarly, anti-apoptotic proteins like Ribosomal S6
inase 2 (RSK2) and FAST bind to the Q/N-rich domains of TIA-1. This
overcomes TIA-1-induced translation repression and stimulates expression of
anti-apoptotic factors [112]. ADAR-1, a dsRNA editing enzyme, has recently
been shown to be a component of SGs following various stresses. This might
indicate that SGs could be a site for RNA editing [113].
Assembly and disassembly: Response to stress results in abortive translation
initiation where the polysomes are reduced to complexes with 48S ribosomes.
Primary aggregation in SGs is attributed to aggregation of these free 48S com-
plexes that include translationally stalled mRNAs. Along with this pool of
mRNAs, there exist many proteins which have undergone posttranslational
modifications. These modifications include phosphorylation, eIF2A [114]; the
lack of phosphorylation [115, 116, 117, 118, 119] ; O-Glc-NAc modification
[120], ubiquitination [120, 121]; acetylation, HDAC6 deacetylase mutants were
defective in SG formation [121]; methylation or the ability to bind methyl
groups via Tudor mRNA-binding domains [122, 123, 124]. These posttrans-
lational modifications facilitate assembly of SGs with the existing proteins
rather than requiring de novo protein synthesis. Similar to that seen in P bod-
ies, proteins with Q/N-rich prion-like domains are constituents of SGs [125]
Aggregation of prion domains can be reversed by expression of heat shock
proteins [126]. An intact microtubule network is required for formation of
SGs, although microtubule depolymerization still results in SGs of smaller size
[127, 121, 128, 129, 130]. Moreover, dynein and kinesin motors have been
implicated in assembly and disassembly, respectively, of SGs [130]. During re-
covery from stress, disassembly of SGs correlates with translational recovery,
although translation initiation does not require complete disassembly of SGs
[131]. On the other hand, translational repression does not require formation
of SGs [130]. Staufen, which stabilizes mRNA-polysome interaction, inhibits
SG assembly [132], and phosphorylation of growth factor receptor-bound pro-
tein 7(Grb7) during stress recovery enables SG disassembly [133]. Recent work
in S. pombe showed presence of stress-induced RNA granules containing ho-
mologs of various mammlian P-body and stress granule components. Contrary
to that in mammalian cells, PABP was observed in these stress-induced gran-
ules. On glucose deprivation, PABP-containing foci accumulated accompanied
by translational downregulation, both in a PKA-dependent manner. On ex-
11
1.4 AU-rich elements (AREs)
posure to hyperosmosis, non-phosphorylatable eIF2A did not block granule
formation but merely delayed it and a similar delay was seen in the disassem-
bly process. Since PKA mutants are capable of forming granules and eIF2A
on hyperosmotic shock, it suggests of the presence of at least two independent
pathways of stress-induced granule formation on glucose starvation [134].
Several reports indicate that P bodies and SGs are dynamically linked struc-
tures [135, 63, 88]. These two types of cytoplasmic RNA granules have been
observed to physically interact with each other and this crosstalk indicates of
cycling of mRNP components between polysomes, P bodies and SGs [6]. Many
P-body components accumulated in SGs during stress, however the viceversa
has not been observed [135]. In studies carried out in S. cerevisiae, blocking P
body formation led to inhibition of SG formation. Blocking SG assembly did
not affect P-body assembly [135, 120]. Moreover, SGs and P bodies can be
spatially completely independent and there can be a direct delivery of mRNAs
from polysomes to SGs without being routed via P bodies [63, 120].
With this, I have described the mRNA degradation process and the cyto-
plasmic RNA granules where the fate of mRNAs is decided. A critical step,
however, is the targeting of specific mRNAs for degradation, without affecting
the global mRNA pools. It is noteworthy that the fate of various eukaryotic
mRNAs is controlled by cis-acting regulatory elements present in their 3’UTRs.
1.4 AU-rich elements (AREs)
A prominent example of cis-acting elements that determine mRNA stability
are the adenylate/uridylate-rich elements (AREs) which have been estimated
to be present in 10-15% of all transcripts [136]. AREs are present in the
3’UTR of mRNAs encoding proteins that require tight regulation. AREs com-
prise well-defined repeats of AUUUA or a nonamer UUAUUUAUU present in
a U/AU-rich context. UUAUUUAUU or its variation UUAUUUAWW (where
W=A/U) are considered to be the minimally functional motifs and two over-
lapping copies of such a nonamer exert the maximum effect on the stability
of the mRNA [137, 138, 139, 140, 141]. The pentamer AUUUA is inactive as
an ARE, unless located in an AU-rich context. On bioinformatical analyses of
AU-rich labile mRNAs, WWWUAUUUAUWW was found to be the 13-base
consensus motif which was located specifically in the 3’UTR [142]. Different
ARE sequences were bionformatically categorized to five classes; classes I-V,
which include mRNAs whose 3’UTRs have five, four, three, two, and one AU-
UUA pentamer, respectively, with a flanking AU context [143], and longer
AREs were linked to shorter half-lives of the mRNA [144, 145].
Functional AREs exist as linear non-structured motifs or as stem-loop struc-
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tures. The sequence motif NNUUNNUUU for HuR binding is functional as
a linear structure and as a linear segment within a secondary structure, the
latter proving to be more efficient [146, 147, 148, 149]. TTP was shown to
bind with high affinity to WWWUAUUUAUWW, but also could bind to mo-
tifs as small as UAUUUAU and UUAUUUAUU. Adenylate residues in the
ARE are a requisite for TTP binding, unlike HuR which is able to bind to a
U-rich tract [150, 151, 152]. Apart from the conservation amongst the ARE
sequences, a general observation was that 3’UTRs bearing AREs are longer
than those devoid of them [136, 153, 154, 155]. Since longer 3’UTRs tend to
offer more miRNA targets, it could be hypothesized that miRNAs and AREs
act synergistically in regulating mRNA stability and/or translation [156].
1.5 ARE-binding proteins (AUBPs)
The cis-acting AREs in the 3’UTR are further assisted by trans-acting pro-
teins called the ARE-binding proteins (AUBPs). Barreau et al. [157] compiled
information on characteristics of binding of prominent AUBPs with AREs be-
longing to different classes in order to perceive a pattern in their interactions.
However, no particular interaction specificity was observed between the types
of AUBPs and AREs. Most AREs were able to bind more than one AUBP, and
likewise the AUBPs were seen to bind to different AREs regardless of the class
the AREs belonged to. However, much of the data considered for this study
was derived from in vitro analyses such as UV-crosslinking or electrophoretic
mobility shift assays (EMSA) and only a few studies covered interactions be-
tween endogenous mRNAs and proteins. All the same, this study brought forth
the idea of redundancy, synergism, and antagonism existing between AUBPs
in binding to AREs in different circumstances. AUBPs regulated the stability,
and in some cases the translation efficiency, of the target mRNAs (discussed
in subsequent sections). A compiled version of all the different AUBPs and
their target ARE-mRNAs is published in [157]; however, only a selected few
are described hereforth.
1.5.1 HuR
The embryonic-lethal abnormal vision (ELAV) family of proteins consists of
four closely related proteins; human antigenR (HuR), HuC, HuD, and Hel-
N1 [158]. HuR has been implicated in stability of ARE-mRNAs. It is a
predominantly nuclear protein, though undergoes nucleo-cytoplasmic shuttling
[159, 160]. It could be by virtue of this shuttling that HuR helps export of
c-fos mRNA out of the nucleus [161]. HuR binds to AREs and increases
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stability and translation of mRNAs involved in growth and proliferation [162].
Knockdown on HuR in MCF7 breast cancer cells decreases the growth potential
of cells which was attributed to decreased transcript and protein levels of
cyclin D1[163]. HuR exists in three different polyadenylated variants, 1.5 kb
testis-specific form, 2.4kb ubiquitously expressed form and a differentiating
neuron-specific 6.0 kb isoform. The 6.0 kb isoform is less stable than the 2.4
kb isoform and is also less expressed. Moreover, neuronal HuB, HuC, HuD, as
well as HuR itself, when overexpressed, bind to the polyadenylation site of the
2.4-kb mRNA leading to alternative polyadenylation generating an extended
HuR 3’-UTR that is translationally less active [164]. HuR was seen to be
associated with regulation of growth on exposure to hypoxic stress [165, 166].
CoCl2-induced hypoxic stress led to caspase-dependent cleavage of HuR. The
HuR-cleavage product-1 thus formed strongly associated with the 3’UTR of c-
myc mRNA, blocked its translation, and as a result reduced cell viability. HuR,
along with AUF1 as a co-factor, binds to a stem-loop structure in the 3’UTR
of p16 mRNA and destabilizes the mRNA by recruiting the RISC complex
[167]. In a recent interesting study, Zheng et al. cloned p53 HuR-binding
site in the 3’UTR of adenoviral vector encoding the luciferase reporter gene.
On transfecting this modified vector into rat submandibular glands or salivary
cells, higher luciferase activity was noticed, ~4-fold compared to that obtained
with the CMV promoter [168].
1.5.2 AUF1
AUF1, also termed as heterogenous nuclear ribonucleoprotein D (hnRNPD),
is essentially a nuclear protein and was the first of the AUBPs to be identified.
The AUF1 family consists of four proteins arising from alternative splicing
of a common pre-mRNA; AUF1-p37, -p40, -p42, and -p45 [169]. AUF1 has
been shown to stabilize some ARE-mRNA targets, e.g., parathyroid hormone
mRNA [170], as well as destabilize some ARE-mRNAs, e.g., IL-3 mRNA [171],
tumor necrosis factor A (TNFA), Granulocyte macrophage colony stimulating
factor (GM-CSF), etc [172]. AUF1-p45, which is the longest of the four iso-
forms and bears the ’GY’ elements, binds to tristetraprolin (TTP) via the GY
elements and increases the mRNA-binding efficiency of TTP by ~5 fold [173].
AUF1 has also been implicated in the hypoxic stress response. von Hippel
Lindau (VHL) protein, product of a tumor suppressor gene, controls oxygen-
responsive gene expression at transcriptional and posttranscriptional levels.
VHL is actively involved in destabilizing the vascular endothelial growth factor
(VEGF) mRNA in normoxic conditions. VEGF bears an ARE in the 3’UTR
which is the binding site for AUF1 and/or HuR. VHL interacts indirectly with
VEGF mRNA via AUF1 and HuR proteins and cause destabilization of VEGF
mRNA. In hypoxic conditions, VHL levels in the cell are lowered but AUF1
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and HuR continue to bind to VEGF mRNA, thus stabilizing the mRNA [174].
AUF1 knockout mice exhibit symptoms of severe endotoxic shock due to high
expression of TNFA and IL-1ß [175].
1.5.3 The TTP family of proteins
The TTP family consists of four proteins; TTP, Butyrate response factor 1
(BRF1), BRF2, and BRF3. These proteins are characterized by the presence of
two zinc finger motifs with a strictly defined intra-finger spacing CX8CX5CX3H
(where X=any amino acid). The interfinger spacing is 18 amino acids and there
is a conserved amino acid lead-in sequence (R/K)YKTEL located immediately
before the first cysteine of each finger [176]. Any alterations in this zinc finger
setup interferes with the RNA binding capacity of these proteins [177]. The
domain including the two zinc fingers is called the TZF domain, and there
exists >70% homology in this domain amongst the TTP family members [176].
The overall homology between the proteins can be seen in Figure 1.1. TTP,
BRF1, and BRF2 when over-expressed induce apoptosis by the mitochondrial
death pathway [178].
Figure 1.1: Homology between the TTP family members. Figure reproduced
from Lykke-Anderson et al. [179]
BRF3 has been the last addition to this family and has yet to be studied in
detail. BRF3 cDNA coded for a 725 amino acid protein, and included 38 con-
secutive repeats of the motif GAALAP or a related variant in its C-terminus.
BRF3 is a rodent-specific protein and BRF3 transcripts were initially detected
only in the placenta and extraembryonic tissues in the mouse [180]. Recent
studies in mouse adipocytes demonstrated presence of BRF3 transcripts at
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low levels [181]. Unlike seen with the other TTP family members [182], mouse
BRF3 when exogenously expressed in HEK293 cells showed an exclusively
cytoplasmic localization, even on treatment with CRM-1-dependent nuclear
export inhibitor, LeptomycinB. This protein held the capacity to promote
deadenylation and degradation of ARE-containing mRNAs [180].
1.5.4 TTP
TTP is a basic proline-rich protein which contains three PPPG repeats [183].
TTP is a phosphoprotein which is induced by several mitogens including
serum, platelet derived growth factor (PDGF), fibroblast growth factor (FGF),
phorbol 12-myristate 13 acetate (PMA), insulin, 12-o-tetradecanoyphorbol-13-
acetate (TPA) [176, 183, 184, 181], etc. Carrick et al. performed time-course
studies to check for the response of TTP to lipopolysaccharide (LPS) induction.
Stimulation of human monocytes caused a rapid induction of TTP mRNA,
reaching 16-fold higher levels in 60 mins of the treatment, as compared to
the unstimulated controls. The levels of TTP exhibited a sharp decline over
the next 2 hrs to plateau at a new level which slightly higher than the ini-
tial unstimulated level [185]. Incidentally, TTP mRNA is labile in unstimu-
lated cells (t1/2=17 mins) but gains more stability on serum stimulation of
cells (t1/2=45 mins), as seen from experiements in fibroblasts [186]. TTP is
known to negatively regulate its own expression by virtue of an ARE in its
3’UTR [187, 188]. Evidence suggests that apolipoprotein-1 (AP-1), a major
component of high-density lipoprotein, was shown to suppress LPS-induced
inflammation via increasing expression of TTP [189].
TTP knockout mice were characterized by myeloid hyperplasia, associated
with cachexia, erosive arthritis, dermatitis, conjunctivitis, and auto-immune
reactions. The myeloid progenitors were insensitive to growth factors. Al-
most all above effects could be negated by administering anti-TNFA antibod-
ies, thus suggesting that TNFA was a target of TTP [190]. TTP knockout
mice developed defects in the hematopoietic stem-progenitor cell compart-
ment, there were increases in the frequemcies of short-term hematopoietic stem
cells (HSCs), multipotent progenitors, and granylocyte-monocyte progenitors,
although no long-term defects were observed [191].
TTP promotes degradation of mRNAs that contain an ARE in their 3’UTR.
TTP binds to a nonameric ARE, UUAUUUAUU [141] in the 3’UTRs of its
target mRNAs. This binding greatly depends on the integrity of the zinc
fingers and cysteine to arginine mutations in any of the two zinc fingers abol-
ishes the binding of TTP to the target mRNAs. Furthermore, this zinc fin-
ger mutant acts in a dominant negative manner [192]. Studies were carried
out in HeLa cells using ß-globin mRNA reporters harbouring the ARE from
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TNFA or GM-CSF [193]. TTP was shown to perform the function of recruiting
these ARE-containing reporter mRNAs to P bodies, since depletion of TTP
hampered the localization of ARE-mRNAs to the P bodies. Besides, over-
expression of TTP slightly enhanced the amounts of ARE-mRNA in the P
bodies when compard to untransfected or control-transfected cells. Expression
of a dominant-negative RNA-binding mutant, TTP-F126N, hampered ARE-
mRNA recruitment to P bodies. Individual over-expression of the N-terminal
domain (NTD), the C-terminal domain (CTD), or the RNA-binding domain
(RBD) were not suffiicient to deliver ARE reporter mRNAs to the P bodies.
The NTD or the CTD along with the RBD was required to recruit the ARE-
mRNAs to P bodies; however, artificial tethering of the NTD or the CTD to
the ARE-mRNA proved sufficient. Accumulation of ARE-mRNAs in P bodies
was enhanced when a component of the mRNA decay machinery was ren-
dered limiting. Taken together, the RBD performed the function of binding
to the target mRNA and the NTD or the CTD were important in delivering
the ARE-mRNAs to the P bodies [193]. In unstressed COS7 cells, TTP lo-
calized to P bodies and SGs. In fact, exogenous expression of TTP increases
the interactions between these two cytoplasmic RNA bodies [63]. TTP also
co-localized with SGs in COS7 cells on experiencing energy starvation by the
action of FCCP, a mitochondrial inhibitor. However, on induction of oxidative
stress by exposure to arsenite, TTP failed to get recruited to stress granules.
MAPK-activated protein kinase-2 (MK2), which is one of the kinases induced
by oxidative stress, induced complex formation between TTP and 14-3-3, and
such complexes were excluded from SGs [194]. Incidentally, the TTP:14-3-3
complex bound to but did not degrade the ARE-mRNA[194]. This hindered
AMD-efficiency was attributed to failure to recruit the deadenylation machin-
ery [195, 196] to the phosphorylated TTP.
Thus, TTP recruits ARE-mRNAs to the possible sites of mRNA degrada-
tion. TTP also facilitates the further steps in mRNA degradation. Lai et al.
[197] via in vitro analyses proved that TTP promotes deadenylation of target
ARE-mRNAs by employing the PARN deadenylase. Since then, studies have
shown that TTP binds to the decapping machinery (Dcp2, Edc3) via the NTD
[60], to the deadenylation machinery (Ccr4-Caf1-Not complex) via the CTD
[198] and to PAN2 [195] to eventually enable mRNA degradation. To date,
TTP has been shown promote AMD of numerous endogenous mRNA targets
involved in inflammation (TNFA, COX-2, GM-CSF, Interleukins (IL)-2, IL-3,
IL-6, IL-8, IL-10, IL-12), cell cycle control (c-myc, c-fos), carcinogenesis, angio-
genesis (VEGF), development (pituitary homeobox 2), protein glycosylation
(1,4-galactosyl transferase), etc (reviewed in [199, 157]). TTP was also shown
to control some target mRNAs by repressing their translation and in this it is
aided by the RcK protein [200].
TTP has been shown to bind to the ARE and destabilize TNFA mRNA
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[190, 201]. On LPS induction, p38 MAPK is stimulated and it phosphorylates
the downstream kinase MK2. Activated MK2 deactivated TTP, prevented as-
sociation of TTP with the TNFA ARE, thus stabilizing the TNFA mRNA.
Furthermore, MK2 also stabilized TTP mRNA causing an increase in cellu-
lar TTP levels [202]. On LPS induction in MK2 defficient mice, the levels of
TNFA mRNA or its secretory properties were not changed, but the TNFA pro-
tein levels were severely reduced. This indicates that MK2 affects translation
of TNFA [203], and it was later demonstrated that this activity was dependent
on the ARE in TNFA [204]. When TTP is removed from this MK2-defficient
system, TNFA levels were elevated resembling the TTP-defficient system. This
could mean that MK2 and TTP together control the biosynthesis of TNFA. An
additional tratment with a p38 inhibitor demonstrated that TNFA and TTP
biosynthesis was also controlled by an additional kinase in absence of MK2
[202]. It is noteworthy that in the same system, IL-6 biosynthesis is controlled
only at the level of mRNA stability and not its translation.
As explained before, inducibility is one way of regulating TTP activity in the
cells. Additionally, after induction, TTP is also controlled posttranslationally.
Kinases from some of the major signaling pathways in the cell have TTP as
their downstream target. These kinases include ERK mitogen-activated pro-
tein kinase (ERK-MAPK), p38 MAPK, JNK, GSK3ß, PKA, PKB, and PKC
[205, 206, 207, 208, 209, 210]. Mutational studies revealed that phosphoryla-
tion of TTP at the serine residues S52 and S178 contributed significantly to
the downregulation of its activity, and that these residues were a target of the
MK2 [194]. The residues flanking S52 and S178 are similar in sequence to the
RSXpSXP or RXXXpSXP motifs which form optimal binding sites for 14-3-3.
14-3-3 is an abundant adaptor protein that modulates activity of its target
proteins. TTP gets phosphorylated on S52 and S178 and binds to 14-3-3 as
seen by electrophoretic mobility shift assays (EMSAs) performed in RAW264.7
cells, and conversion of both these serines together to alanines was required to
abolish 14-3-3 binding to TTP [194]. Interaction of TTP with 14-3-3 enhances
cytoplasmic localization of TTP, protects TTP from dephosphorylation, and
prevents degradation of TTP by the proteasome [211, 212, 213]. When the
stabilizing signal dissipates, phosphatase PP2A dephosphorylates TTP and
activates it and renders it capable of degrading transcripts and limiting their
expression [214].
14-3-3 proteins:
14-3-3 is an abundant modulator of activity of many proteins and exists in
nine homologous family members in mammals (alpha, beta, gamma, delta,
epsilon, eta, sigma, tau, and zeta). It binds to target proteins that bear the
optimal binding motif for 14-3-3, RSXpSXP and/or RXXXpSXP, where the
serines are pre-phosphorylated [215, 216, 217]. More recently, a new consensus
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motif has been included. Ganguly et al. reported of six known interacting
proteins with a novel carboxy terminal, pS/pT-X(1-2)-COOH motif (where
X is not a proline) [218]. This SWTX motif overrides the RKR motif which
is the endoplasmic reticulum localization signal and redirects membrane pro-
teins to the cell surface [219, 220]. All the same, some recent studies indicate
that phosphorylation is necessary but not sufficient for 14-3-3 binging and
that more anchor residues might be required to stabilize the interaction [221].
Computational approaches have suggested that > 90% of the 14-3-3 binding
sites lie in disordered regions of their target proteins [222]. Since 14-3-3 sites
are usually present as a pair, Johnson et al suggested that 14-3-3 might act
in integration of signals from different pathways, specially if both the binding
sites are phosphorylated by different kinases [223].
SMG7 protein has been implicated in the dephosphorylation of UPF1 from
the NMD pathway [224]. The N-terminal of SMG7 contains a 14-3-3-like-
domain. In SMG7, there exist residues which resemble the phosphoserine
binding residues of 14-3-3. Mutation of these residues impairs binding of SMG7
to UPF1 and the recruitment of UPF1 to cytoplasmic RNA foci. The same
set of residues is seen in SMG5 and SMG6 [225].
1.5.5 BRF1
BRF1 was identified through a genetic screen designed to identify novel AUBPs.
Stoecklin et al. [226] generated a reporter plasmid which consisted of a GFP
reporter gene, flanked by the 5’UTR and the ARE-containing 3’UTR of hu-
man IL-3 gene. This reporter was stably transfected into HT1080 cells lead-
ing to several clones, one of which was HTwt16. HTwt16 are wildtype cells
where AMD is efficient, hence the reporter ARE-mRNA is degraded, and con-
sequently the GFP expression is low. The amount of GFP expressed could
be estimated by performing fluorescence-activated cell sorting (FACS). These
HTwt16 cells were then subjected to 8-12 rounds of random chemical mutage-
nesis by exposure to ICR191, which is a frameshift mutagen. Of the surviving
population, 3 clones showed high levels of GFP expression, implying impaired
AMD efficiency. Cells from one of these clones, SlowC, led to an ~8-fold in-
crease in the half life of ARE-containing reporter mRNA. SlowC was subjected
to gene complementation assays to determine which gene was responsible for
the impaired AMD [227]. To this end, the SlowC cells were infected with
a retroviral cDNA library which was generated using size-fractionated cDNA
from HT1080 cells. Clones showing lower levels of AMD compared to that
seen in SlowC cells were chosen via FACS. Figure 1.2 depicts the FACS pro-
files of the HTwt16, SlowC, and CM1 clone. As seen in the FACS profiles, the
GFP intensity was plotted along the X-axis. HTwt16 shows low levels of GFP
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which is a signature of wildtype cells with efficient AMD. The SlowC cells have
impaired AMD efficiency, hence showed higher levels of expressed GFP. CM1
displayed lower GFP intensity as compared to that seen in SlowC cells, indi-
cating restored AMD. Adjacent to the FACS profiles are the GFP-IL3 reporter
mRNA decay experiments which demonstrate the difference in half-lives of the
GFP-IL3 reporter mRNA in HTwt16, SlowC, and the CM1 cell lines. The gene
responsible for restoring AMD activity of CM1 cells was later identified to be
BRF1. The genotype of SlowC was analysed and it was observed that both
copies of BRF1 in SlowC cells harboured out-of-frame stop codons which occur
after 73 and 123 amino acids in the two BRF1 alleles. Phenotypic analyses
revealed the absence of a full-length BRF1 protein. Thereforth, SlowC cells
have been treated as a homozygous knockout for BRF1 gene. This SlowC cell
line has been used in the study described in this thesis.
Figure 1.2: The SlowC cell line. HT1080 cells were stably transfected with a plasmid
construct consisting of GFP reporter gene located between the IL-3 5’ UTR and the
ARE-containing 3’ UTR of IL-3. The resultant cell line, HTwt16, was subjected to ten
rounds of random chemical mutagenesis. Clones were selected based on increase in GFP
intensity on performing FACS analyses. Gene complementation assay was carried out
by transfecting clones with retroviral-cDNA library (cDNA was generated using HT1080
genomic DNA). Clones over-expressing BRF1 protein was identified as being able to
restore AMD efficiency. Both alleles of BRF1 were sequenced to reveal premature stop
codons. Figure reproduced from Stoecklin et al. [227].
Stumpo et al [228], created a BRF1 knockout mouse. All knockout embryos
died in utero by embryonic day 11 (E11). Two-thirds of these deaths were
attributed to failure of chorio-allantoic fusiion. In the remainder embryos, by
E10.5 the placentas showed decreased cell division and atropy of trophoblast
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layers. Neural tube defects were seen which were a consequence of placental
abnormalities. Fibroblasts derived from knockout embryos had normal levels
of fully polyadenylated compared to deadenylated GM-CSF mRNA and the
mRNA turnover rate was normal. Bell et al. [229] investigated the placental
defects of BRF1 knockout mice in greater detail. Expansion of primitive ery-
throid cells appeared hampered. Defective development of the mutant mice
was due to elevated expression of VEGF-A in embroys and in the mutant em-
bryonic fibroblasts cultured under normoxic or hypoxic conditions. VEGF-A
mRNA decay rates remained unaltered. The increase in levels of VEGF-A
protein was associated with enhanced association of VEGF-A mRNA with
polysomes, indicating that BRF1 controls translation of VEGF-A mRNA. An-
other study revealed that BRF1 destabilized Stat5b mRNA and this resulted
in a drastic decrease in formation of erythroid colonies indicating the role of
BRF1 in hematopoiesis [230]. BRF1 mRNA levels were controlled by parathy-
roid hormone (PTH) and bone morphogenetic protein 2 (BMP-2) in mouse
osteoblasts [231].
BRF1 activity is regulated in a manner very similar seen in TTP. In BRF1, ser-
ines S92 and S203 are phosphorylated by MK2 and Protein kinase-BA (PKBA)
enzymes, result in BRF1 binding to 14-3-3 and its ARE-mRNA destabilizing
activity is impaired [232, 211, 233]. Furthermore BFR1 has been shown to
recruit ARE-mRNA to P bodies [193].
1.5.6 BRF2
The Blackshear group attempted to create BRF2 knockout mice. In their first
attempt, the mice still produced a BRF2 protein which lacked the first exon
but expressed the second exon along with a significant portion of the single
intron. rest of the protein taking a AUG in the intron as an initiation codon.
The homozygous F1 progeny were healthy, but the females were sterile despite
having a normal reproductive system. The death of homozygous F2 generation
embryos occured due to arrest at the two-cell stage, which is a characteristic
of maternal mRNA defficiency [234]. The same group later generated a BRF2
complete knockout mouse. Homozygous BRF2 knockout mice died within ~2
weeks of birth. All the knockout mice necropsied, had pallor of skin often
accompanied by hemorrhage, usually in the intestines. There was an over-
all defect in hematopoietic development with significantly decreased levels of
red blood cells, white blood cells, hemoglobin, and hematocrit. Myeloid and
megakaryocyte populations appeared reduced [235]. Mutations in the BRF2
gene have been observed in many leukemia patients / cell lines [236]. Dou-
ble knockout mice with a conditional deletion of BRF1 and BRF2 underwent
defective thymopoiesis and developed T-cell acute lymbhoblastic leukemia (T-
21
1.6 Aim of the study
ALL). Notch-1, which plays and important role in thymopoiesis and bears a
nonameric ARE in the 3’UTR, was suggested to be a target. [237].
1.6 Aim of the study
The TTP family is a prominent part of the AUBPs. Although bearing high
homology amongst each other, there are some significant differences, mostly
regarding cellular presence. Carrick et al. established that the cellular mRNA
levels of the TTP family members vary in different tissues and cell lines [238].
Serum and LPS have been known to rapidly induce TTP [185]. However, there
are divided views about BRF1 and BRF2, indicating their upregulation [185] or
downregulation (W.S. Lai and P.J. Blackshear, unpublished data, mentioned
in [173]) on LPS treatment. Nevertheless, the change in BRF1 and BRF2
levels, if any, was marginal and not comparable to that of TTP. Insulin was
shown to upregulate TTP mRNA and protein levels to a considerable extent
[181, 183]; however, BRF1 and BRF2 mRNA levels were downregulated [181].
TTP, BRF1, and BRF2 can promote degradation of ARE-mRNAs in an in
vitro setup with comparable efficiencies. However, it is clear from the differ-
ences in the respective knockout mice that each member has distinct functions
and is active in a highly temporal manner. It also says that one member of the
TTP family cannot be substituted by another in the in vivo context. The en-
dogenous ARE-mRNA target specificities are different. A similar observation
is regarding the SlowC cells, where TTP and BRF2 are possibly unaltered but
still the AMD remains impaired. This points out to a higher level of regulation
amongst the three members. Only limited information is available on BRF2.
Hence, it would thus be interesting to question the role of BRF2 in the cell
and investigate the regulation of its activity.
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ARE-mediated mRNA decay
2.1 BRF2 mRNA levels are elevated in SlowC
cells
SlowC cells lack functional BRF1 protein [227]. Over-expression of BRF1 in
SlowC cell lines restores the AMD capacity of these cells. The questions arose
as to a) why the endogenous level of BRF2 was not sufficient to compensate for
AMD and whether BRF2 was needed in amounts higher than the endogenous
levels, b) whether BRF1 stabilizes BRF2, and therefore in absence of BRF1,
eventually BRF2 too is destabilized, and c) whether BRF1 and BRF2 are
functional as a heterodimer. I tried to address some of the questions in the
following section.
The first question I asked was whether BRF1 regulates levels of BRF2. If
it did, SlowC cells which lack BRF1 should show altered levels of BRF2 as
compared to HTwt16. I measured the mRNA levels of the BRF1 and BRF2
genes in HTwt16 and SlowC cells to find out the effect of the absence of BRF1
on BRF2 mRNA levels. I performed RT-qPCR using two sets of primers each
to determine BRF1 and BRF2 mRNA levels Figure 2.1. Nucleolin mRNA was
used as an internal control against which the mRNA levels of BRF1 and BRF2
were normalized. Three independent biological repeats and three technical
repeats PCR were performed. For each set of primers, mean mRNA level of
the gene in HTwt16 was used as reference and set to 100%. Thus, BRF1 and
BRF2 mRNA levels in SlowC were respectively represented as a percentage of
BRF1 and BRF2 mRNA levels in HTwt16.
Both BRF1 alleles in SlowC contain premature stop codons; therefore, BRF1
mRNA levels remain unchanged. This finding was confirmed by RT-qPCR
data as seen in [Figure 2.1]. Additionally, I observed a nearly 2-fold increase in
the SlowC BRF2 mRNA levels when compared to those in HTwt16. Whether
this difference holds true at the protein level remains to be probed.
Estimation of protein levels of both the above genes in SlowC cells, which
would be the ideal experimental design, was not possible due to the lack of
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Figure 2.1: mRNA levels of BRF1 and BRF2 in HTwt16 and SlowC cells.
mRNA levels of BRF1 and BRF2 in HTwt16 and SlowC cells were quantified byRT-
qPCR using two distinct sets of primers per experimental gene. Values were normalized
against nucleolin mRNA. Values are mean ± s.e.m of three technical replicates and three
independent biological repeats.
antibodies that are highly specific towards BRF1 or BRF2. The existing rab-
bit polyclonal antibody [239] did not give conclusive results. Figure 2.2:Panel
A shows a western blot where I analysed lysates from different cell lines as
indicated for endogenous BRF1/2 protein expression. The filled arrow shows
the possible position of BRF1; this band is seen in HT1080 lysate (Lane 5)
and is missing from SlowC (Lane 6) confirming the absence of BRF1 in SlowC.
Apart from this, BRF1 is detected in the U2OS cells. The empty arrow shows
a band of low intensity which may correspond to BRF2. Panel B shows HA-
BRF2 over-expressed in HTwt16 and SlowC cells (Lanes 9,10, respectively).
Transient expression consistently shows HA-BRF2 to run between 60-70 kDa,
while the predicted molecular weight of BRF2 is 51 kDa. I attempted rais-
ing polyclonal antibodies against mutually heterologous regions in BRF1 and
BRF2. However, the obtained antibodies could detect only over-expressed
BRF1 and BRF2 Figure 2.3.
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Figure 2.2: Protein levels of BRF1 and BRF2 in different cell lines. Panel A:
Laemmli lysates of indicated cell lines were resolved on 10% polyacrylamide gels, subjected
to western blotting, and probed with a polyclonal antibody against BRF proteins [239].
Panel B: HA-BRF2 transiently over-expressed in HEK293 cells.
2.2 Stable over-expression of BRF2 in SlowC cell
lines
Assuming that BRF2 protein is upregulated ~2-fold in SlowC cells, why does
this increase not restore the AMD capacity of the SlowC cells? To address this
question, I initially tested whether BRF2 promotes mRNA degradation in an
ARE-dependent manner. To this end, I used SlowC cells which encode a stably
transfected ARE-containing reporter mRNA as in Figure 2.4. This reporter
has a GFP gene inserted between the IL-3 5’ UTR and the ARE-containing 3’
UTR of IL-3 (henceforth termed as the GFP-IL3 reporter). In wildtype cells,
efficient AMD leads to degradation of reporter mRNA and results in lowered
GFP signal intensities in FACS and lesser residual reporter-mRNA in northern
blotting experiments.
My goal was to stably over-express HA-BFR1 and HA-BRF2 in SlowC cells.
After selecting for survival in presence of the drug, G418, individual clones
were isolated and several such clones were screened using FACS for clones
showing a GFP signal lower than that in SlowC cells [227]. With regard to
BRF2 stable over-expression, FACS analyses identified two clones in which the
GFP signal was lower than that in the SlowC cells, hinting at efficient reporter
GFP-IL3 mRNA decay. Positive and negative clones each were selected for
SlowC cells expressing HA-BRF1 or HA-BRF2. These four clones were fol-
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Figure 2.3: Polyclonal antibodies recognize only over-expressed BRF1 and
BRF2 proteins. Polyclonal antibodies were raised in rabbits against mutually exclu-
sive regions of BRF1 and BRF2 (two rabbits immunized with GST-BRF1:aa231-288; one
rabbit immunized with GST-BRF2:aa1-117). The final sera that was raised against the
two antigens did not cross-react with the other TTP family members. They however
recognized only the over-expressed forms of BRF1(Lanes 2, 6) or BRF2 (Lane 11). All
the three sera fail to recognize endogenous BRF1/BRF2 proteins (Lanes 4, 8, 12).
lowed up with actinomycinD chase experiments to study the degradation of
the reporter mRNA. ActinomycinD blocks polymerase II transcription; hence,
the 0-hr timepoint depicts steady-state levels of the reporter RNA.
Cell lines used in the assay were: HTwt16 (effective AMD, therefore less re-
porter mRNA, and less GFP expressed) and SlowC (compromised AMD, there-
fore more reporter mRNA, and more GFP expressed) as reference standards,
positive clone for SlowC-BRF1 (SC-B1-1), negative clone for SlowC-BRF1
(SC-B1-2), first positive clone for SlowC-BRF2-clone I (SC-B2-1), second pos-
itive clone for SlowC-BRF2 (SC-B2-2), and a negative clone for SlowC-BRF2
(SC-B2-3). Northern blotting analyses were used to detect the GFP-IL3 re-
porter mRNA while RPS7 mRNA served as a loading control. FACS was
performed of an additional sample withdrawn from all above cell lines at the
0-hr timepoint. FACS analyses showed that the GFP signal in SC-B1-1, SC-
B2-1, and SC-B2-2 had decreased, suggesting restored AMD. Northern blotting
resulted in an extremely weak signal with a RNA probe specific for the IL-
3 3’ UTR. These low signal intensities represented low steady-state levels of
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Figure 2.4: The GFP-IL3 reporter mRNA. HTwt16 and SlowC stably express the
GFP-IL3 reporter which serves to monitor AMD. Efficient AMD leads to degradation
of reporter mRNA and results in lowered GFP signal intensities in FACS and northern
blotting experiments. When AMD is compromised, the GFP-IL3 reporter mRNA is
not degraded and results in high GFP intensity when estimated by FACS and northern
blotting.
the reporter mRNA. This problem was reporter-mRNA specific, since RPS7
mRNA was present in abundant quantities. Low expression could be due to
the GFP-IL3 reporter-mRNA transcription being driven by the IL-3 promoter,
and not a strong promoter like the CMV promoter. Moreover, efficient AMD
decreased the steady-state levels further. Thus, due to the low levels of the
GFP-IL3 reporter, it proved difficult to assess the degradation rates of the
above clones. Nevertheless, SC-B1-2, SC-B2-1, and SC-B2-2 showed reduced
reporter mRNA levels suggesting higher AMD efficiency than in SlowC cells.
[FACS and Northern blotting in Figure 2.5].
In order to confirm that these clones in fact over-express HA-BRF2, I carried
out western blotting analyses of lysates from different clones, and probed them
with an anti-HA antibody to only detect the exogenously expressed BRF1/2
protein Figure 2.6. BRF1 protein is seen at the expected position (Lane 5).
Incidentally, lysates from both seemingly BRF2-positive positive clones showed
expression of an HA-tagged protein at approximately 35 kDa size [Lanes 7,8].
This protein is much smaller than the full-length BRF2 protein. It may repre-
sent the N-terminal portion of BRF2 since the HA tag is detected. This could
be due to improper insertion of the transfected plasmid leading to expression
of a truncated version of HA-BRF2 or posttranslational proteolytic processing
of full-length BRF2 leading to a remainder N-terminal fragment. The single
MG132 (proteasome inhibitor) experiment I performed to check for proteolysis
of HA-BRF2 via the proteasome did not argue in favour of proteolytic process-
ing, and genomic DNA analyses posed technical problems (data not shown).
While it is not clear how the protein fragment of BRF2 was generated, it is
interesting to note that the fragment appears to be active in promoting AMD.
I performed a new round of stable transfection, for which the plasmid was lin-
earized with DraIII restriction enzyme. This ensured that prior to transfection,
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I started with a linear DNA having the complete HA-BRF2 gene and its aux-
iliary regions. The second attempt of BRF2 stable transfection in SlowC cells
yielded two positive clones, SC-B2-4 and SC-B2-5, which exhibited low levels of
GFP by a FACS analysis and SC-B2-6 as a negative control [Figure 2.7:Panel
A]. Western blotting shown in Panel B indicated SC-B2-1 expressing full-length
HA-BRF2 (Lane 2). Surprisingly, the second clone SC-B2-2 expressed HA-
BRF2 of a size around 35 kDa (Panel B, Lane 3). I did not examine this clone
further, but continued working with SC-B2-4 which expressed the full-length
HA-BRF2
Stable cell clones were expanded and serially passaged over ~4 months. How-
ever, after this period of time, the FACS profiles for SC-B2-P appeared to
change, displaying higher GFP signal intensities, indicating a gradual loss of
AMD capacity [SC-B2-P in Figure 2.8:Panel A]. Western blotting analyses
at this point of time indicated a drastic reduction in the level of HA-BRF2
expressed in these stable clones as compared to those in the initial passages
[Figure 2.8: Panel B, Lane 3, 2 hrs exposure of film]. This line of work was
terminated here, since the effect produced by this mildly-expressed HA-BRF2
would be out of the sensitivity limit of my experiments. Hereon, I switched to
a transient-transfection system for studying the role of BRF2 in AMD.
2.3 Transient over-expression of BRF2
destabilizes ARE-containing mRNAs
I used a transient transfection system in HeLa cells where I over-expressed HA-
tagged BRF2, the Tet-off transactivator, together with a plasmid encoding an
mRNA reporter gene driven by a Tetracycline-sensitive promoter. The reporter
consists of a rabbit ß-globin gene with or without the 53 nt-long TNFA ARE in
its 3’ UTR. The scheme for this reporter is given in [Figure 2.9]. The Tet-off
system [240] made it possible to shut off reporter transcription by addition
of doxycycline, which determined the 0-hr timepoint for the reporter mRNA
decay assay. In such doxycycline-chase assays, samples were collected over
a timecourse of 3 hours and total RNA was isolated. Northern blotting was
carried out using RNA probes against ß-globin mRNA and nucleolin mRNA as
a loading control. In Panel A, where a ß-globin reporter gene devoid of ARE
was transfected, no degradation was detected, irrespective of over-expressed
HA-BRF2. In Panel B, where samples were transfected with the ß-globin-
ARE reporter gene, reporter mRNA decay was accelerated when HA-BRF2
was co-expressed. Calculation of half-lives of the reporter mRNA in all four
experimental conditions shows that HA-BRF2 reduces the half-life of the ß-
globin-ARE mRNA from 3.8 hrs to 1.1 hrs [Figure 2.9: Panel B]. Thus, BFR2
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promotes mRNA degradation in an ARE-specific manner.
2.4 DISCUSSION
BRF2 mRNA shows elevated levels in SlowC cells: BRF1 and BFR2 are ho-
mologous proteins belonging to the TTP family of proteins. The absence of a
functional BRF1 protein in SlowC cells leads to the loss of AMD activity of
the cell. Since limited data is available on both proteins, it is not known if
the effects of the two are redundant or additive. Moreover, it is possible that
BRF1 regulates BRF2 levels, and viceversa. BRF1 has an established role in
AMD as a protein that binds to the ARE and triggers rapid degradation of
the bound mRNA [227]. Therefore, it was interesting to investigate whether
an AU-rich element exists in the 3’ UTR of the BRF2 gene which could make
it a target of BRF1. Literature published so far does not acknowledge BRF2
as an ARE-containing gene. Hence, I processed the spliced mRNA sequence
of BRF2 (NM_006887.4, NCBI GenBank) using the AREScore algorithm de-
signed by Spasic et al [241]. This algorithm identified five AUUUA pentamers
dispersed over the 3’ UTR of the BRF2 gene [Figure 2.10]. This makes BRF2
a candidate AMD substrate to potentially undergo AMD in order to regulate
its own levels. BRF1 might also control BRF2 at the protein level. However,
SlowC cells were generated by random chemical mutagenesis. It is likely that
more genes were mutated apart from BRF1, which have not been scored for.
Such mutations may favour altered BRF2 regulation. Hence, more detailed
experiments need to be performed, e.g., BRF2 protein levels in SlowC and
SC-B1-1 (SlowC over-expressing HA-BRF1) should be compared to address
any relation between BRF1 and BRF2 at the protein level.
Stable over-expression of BRF2 in SlowC cell lines: Initial passages of SlowC
cells over-expressing HA-BRF2 indicated a restored AMD capacity. However,
it is possible that the gradual loss of over-expressed BRF2 protein could have
contributed to the FACS profiles resembling those of SlowC untransfected cells.
Earlier studies on over-expression of BRF2 yielded similar outcomes. BRF2
over-expression was reported to trigger apoptotic-like cell death. When quanti-
fied, the percentage of cell death was 10.5% at 24 hrs and 31.9% at 3 days after
transfection of BRF2. This was linked to the p53-dependent apoptosis pathway
[242]. In an older study, over-expression of TTP, BRF1, and BRF2 had been
shown to stimulate the mitochondrial death machinery and induce apoptosis
[178]. It is thus a reasonable assumption that in my stable transfection exper-
iments, the cells that originally expressed high levels of HA-BRF2 gradually
got eliminated due to apoptosis-like cell death. The remainder could be cells
with little expression of HA-BRF2 where apoptosis is not yet triggered. In a
transient transfection scenario, cells are allowed to grow only upto 48 hrs after
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transfection with BRF2 plasmid before being lysed for experimental purposes.
Presumably, this would be a time frame where the cells are not apoptotic.
BRF2 degrades ARE-containing mRNAs: Lai et al. [197] had performed cell-
free deadenylation assays to show that TTP, BRF1, and BRF2 are able to
deadenylate ARE-containing mRNA reporters. The reactions in this assay
were quenched after 60 mins, and the Xenopus ortholog of BRF2, xC3H-3, was
used. This demonstrated that deadenylation could be one of the early steps of
the human ortholog of BRF2 as well. However, this study did not elaborate
on therole of BRF2 in AMD. I chose to study the AMD abilities of BRF2 in a
more physiological system as compared to the one in the above study. Since
steady state levels for each mRNA are determined by the rates of transcription
and degradation, the doxycycline chase assay is an elegant way of uncoupling
these two processes and studying only the mRNA decay part. Addition of
doxycycline ensures highly-specific shutdown of reporter gene transcription.
Therefore, the results seen are solely a readout of mRNA degradation. In
the described assay, BRF2 causes degradation of the ARE-containing reporter
mRNA, which adds it to the list of proteins that destabilize ARE-containing
mRNAs. I had to employ an exogenous over-expression system for BRF2
throughout this study, since the endogenous levels of BRF2 were not sufficient
for the kind of experiments I needed to perform (Figure 2.2). Now that the
assay to measure mRNA decay was established, regulation of BRF2 activity
and players involved therewith were investigated further.
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Figure 2.5: FACS and Northern blotting analyses of stable SlowC-BRF1 and
SlowC-BRF2 clones: Attempt I. ActinomycinD-chase assays were cerried out over a
period of 3 hrs followed by northern blotting experiments. Cell lines used in the assay
were: HTwt16 and SlowC (as reference standards), positive clone for SlowC-BRF1 (SC-
B1-1), negative clone for SlowC-BRF1 (SC-B1-2), first positive clone for SlowC-BRF2-
clone I (SC-B2-1), second positive clone for SlowC-BRF2 (SC-B2-2), and a negative clone
for SlowC-BRF2 (SC-B2-3). RNA probes used were specific for IL-3 3’UTR to detect the
reporter gene and for RPS7 mRNA as a loading control. FACS was performed with an
additional sample withdrawn from all above cell lines at the 0-hr timepoint.
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Figure 2.6: Expression of BRF1 or BRF2 protein in respective stable clones.
Laemmli lysates of indicated stable cell clones were resolved on 10% polyacrylamide gels,
subjected to western blotting, and probed with a mouse monoclonal anti-HA antibody..
Molecular weights are indicated in kDa.
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Figure 2.7: FACS profiles and expression of BRF2 protein in stable SlowC-
BRF2 clones: Attempt II. Panel A: pcDNA-HA-BRF2 plasmid was DraIII-linearized
prior to transfection. FACS was performed with samples from cell lines indicated. Panel
B: Laemmli lysates of indicated stable cell clones were resolved on 10% polyacrylamide
gels, subjected to western blotting, and probed with a mouse monoclonal anti-HA anti-
body. Molecular weights are indicated in kDa.
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Figure 2.8: FACS profiles and expression of BRF2 protein in stable SlowC-
BRF2 clones after serial passages. Stable cell clones were expanded and serially
passaged over ~4 months. Panel A: FACS was performed with samples from cell lines
indicated. Panel B: Laemmli lysates of indicated stable cell clones were resolved on 10%
polyacrylamide gels, subjected to western blotting, and probed with a mouse monoclonal
anti-HA antibody. . Molecular weights are indicated in kDa.
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Figure 2.9: BRF2 degrades mRNAs in an ARE-dependent manner. A Tet-off
system was employed and HeLa cells were transfected with an empty-vector or with a
plasmid encoding HA-BRF2. Transfections in PanelA included the ß-globin reporter gene
lacking the ARE in the 3’ UTR; and those in Panel B included the ß-globin-ARE reporter
gene. Northern blotting RNA probes used were against ß-globin, reporter gene; and
nucleolin, loading control. Reporter mRNA levels were normalized to nucleolin mRNA
levels. The 0-hr timepoint is set to 100%. Graphs of reporter mRNA levels vs. time are
plotted. Half-lives of the reporter mRNA in each setup is indicated.
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Figure 2.10: Putative AU-rich elements in the 3’UTR of BRF2 as predicted
by the AREScore algorithm. The spliced mRNA sequence of BRF2 (NM_006887.4,
NCBI GenBank) was analysed using the AREScore algorithm which predicted five AU-
rich pentamers at nt positions 3133, 3142, 3190, 3357, and 3378 which are located in the
3’UTR of BRF2 mRNA. Residues (3100-3399) of BRF2 mRNA are given in the figure
and the AU-rich pentamers are highlighted.
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3.1 BRF2 binds to 14-3-3 protein
3.1.1 BRF2 interaction with 14-3-3 is dependent on
phosphorylation
14-3-3 is an abundant adaptor protein that binds to and modulates the activ-
ity of various proteins in the cell [243]. Here, I sought to find out if 14-3-3
modulates the AMD activity of BRF2. I performed co-immunoprecipitation
experiments to check for possible interaction between BRF2 and 14-3-3. The
questions addressed were (a) whether BRF2 interacts with 14-3-3, and if yes,
(b) whether this interaction is phosphorylation-dependent.
To answer these, I performed co-immunoprecipitation (co-IP) experiments in
HEK293 cells using the GFP-binder beads [Figure 3.1]. The GFP-binder is
a bacterially-expressed stable monomer of a 13 kDa binding fragment of the
heavy chain antibody of the llama. Recombinant GFP-binder protein is immo-
bilized on NHS-sepharose beads and used in co-IP experiments to pull down
GFP tagged proteins.This fragment is known to interact strongly and specif-
ically with GFP [244]. YFP bears high homology with GFP; hence, interacts
effiently with the GFP binder. I used YFP-BRF2 as a bait protein. 14-3-3over-
expression was not necesary, since the endogenous levels are abundant. Two
sets of co-IPs were performed [Figure 3.2]. The first set included phosphatase
inhibitors, namely, sodium vanadate, sodium fluoride, and okadaic acid in the
lysis buffer. This would preserve the phosphorylation status of proteins and
enable possible binding between BRF2 and 14-3-3 in case this interaction de-
pended on covalently linked phosphate groups (Lanes 1,3). The second set
included phage lambda phosphatase in the lysis buffer which would dephos-
phorylate serines and threonines on the proteins after lysis (Lanes 2,4). BRF2
was able to pull down 14-3-3 (Lane 3) in the untreated set. In the set treated
with phage lambda phosphatase, only a minimal amount of 14-3-3 was pulled
down (Lane 4), which indicates that the interaction was significantly reduced
upon loss of phosphorylation. In Lanes 1,2, which represent the empty-vector
(YFP-only) control, no 14-3-3 is detected confirming that 14-3-3 does not inter-
act with the YFP tag. This empty-vector control has been used in all further
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co-IP experiments. Careful observation reveals two similar molecular weight
14-3-3 bands hinting at a possible heterodimer containing 14-3-3epsilon. With
this, I demonstrated that BRF2 interacts with 14-3-3 and that this interaction
is dependent on phosphorylation.
Figure 3.1: The GFP binder system. The GFP-binder is a bacterially-expressed
stable monomer of a 13 kDa binding fragment of the heavy chain antibody of the llama.
Recombinant GFP-binder protein is immobilized on NHS-sepharose beads and used in
co-IP experiments to pull down GFP tagged proteins.
During the standardization phase of the co-IP experiments, I had used HT1080
cells as the SlowC cells are derivatives of HT1080. However, expressing suf-
ficient amounts of BRF2 in these cells proved to be difficult because of the
low transfection efficiency and inconsistent expression of BRF2. Thereforth,
I used HEK293 cells since they support robust protein expression. Moreover,
previously I used HA-BFR2 to pull down 14-3-3. Inadequate amounts of 14-
3-3 were pulled down, which made its western blot detection difficult, with
rarely-consistent results. Hence, I shifted to using the GFP-binder which has
high affinity for YFP. This made the co-IP considerably more efficient and
pulled down larger amounts of 14-3-3 in a reproducible manner.
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Figure 3.2: BRF2 binds to 14-3-3 in a phosphorylation-dependent manner.
HEK293 cells were transiently transfected with plasmids encoding YFP-only or YFP-
BRF2. Cytoplasmic lysates were prepared 24 hrs after transfection. The two sets con-
sisted of lysates including phosphatase inhibitors (Lanes 1,3) or lysates including 1 unit/µl
of lambda phage phosphatase (lambda PPase) (Lanes 2,4) in the lysis buffers. co-IP ex-
periments were carried out to purify YFP-tagged proteins along with their interacting
partners using the GFP-binder beads. Eluted proteins were resolved on 10 % SDS poly-
acrylamide gels. Western blotting analyses were carried out using an anti-GFP and an
anti-14-3-3 antibody.
3.1.2 BRF2 binds to 14-3-3 via serine residues S123 and
S257
14-3-3 binding to TTP [245] and BRF1 [232, 211] has already been studied in
detail. Keeping the extensive homology between BRF2 and above two proteins
in mind, I considered 14-3-3 to be a putative interacting partner of BRF2.
3.1.2.1 BRF2-S123,257A double mutant shows reduced binding to
14-3-3
I wanted to determine the 14-3-3 binding sites of BRF2. Considering the target
sequence criteria for 14-3-3 binding [215, 216, 217], the BRF2 protein sequence
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was scanned for sequences which bore homology with the optimal sequence
motifs recognized by 14-3-3: RSXpSXP and RXXXpSXP. No sequence with
100% homology could be identified. However, there were multiple sequences
that were similar to these motifs. I chose to work on three sequences that
were closest to the optimal sequence; RDRSFS (S123), KLHHSLS (S257),
and RLSISDD (S492). The sequences flanking S123 and S257 of BRF2 are
conserved among the TTP family of proteins [Figure 3.3].
Figure 3.3: 14-3-3 binding sites of TTP, BRF1, and BRF2 bear homology with
each other.
I generated three mutants by PCR-based site-directed mutagenesis of BRF2
for the residues S123, S257, and S492, replacing the serines with alanines,
thus abolishing putative phosphorylation at these sites [Figure 3.4: Panel A].
Additionally, I created a S123,257A double mutant. co-IP experiments were
performed in HEK293 cells using the GFP-binder. BRF2 wildtype or BRF2
mutants were used as a bait to co-IP endogenous 14-3-3. Phosphatase in-
hibitors were added to all co-IPs to preserve the phosphorylation status of the
interacting proteins. Amounts of plasmid DNA was adjusted to achieve equal
amounts of expression of all BRF2 constructs. Figure 3.4: Panel B demon-
strates that all three single S to A mutants of BRF2 continue to bind to 14-3-3
[Panel B, lanes 3-5]. However, barely-detectable amounts of 14-3-3 were de-
tected for the double mutant BRF2, S123,257A [Panel B, Lane 6]. The input
amounts of 14-3-3 were equal in all samples. YFP-only control (Lane 1) shows
no interaction with 14-3-3. Taken together, this experiment indicated that the
interaction between 14-3-3 and BRF2 is dependent on simultaneous phospho-
rylation at both residues S123 and S257A of BRF2 and these two sites bear
homology with the 14-3-3 binding sites of TTP and BRF1 [Figure 3.3]. At
this point, it was interesting to know if artificially increasing the phosphoryla-
tion of BRF2 would restore/enhance the 14-3-3 binding capacity of this double
mutant.
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3.1.2.2 BRF2-S123,257A double mutant shows reduced binding to
14-3-3 on exposure to arsenite-induced oxidative stress
Since the kinase that phosphorylates BRF2 is not known, I followed the ap-
proach to non-specifically increase the phosphorylation levels of proteins in the
cell. Arsenite causes oxidative stress in the cell, leadnig toa net increase in the
phosphorylation status of many proteins due to activation of various kinases.
If cells were exposed to arsenite, it is a reasonable assumption that BRF2
phosphorylation would get enhanced. These higher levels of phosphorylation
would result in enhanced binding to 14-3-3.
In order to investigate this, co-IP experiments were carried out in transfected
HEK293 cells after subjecting the cells to oxidative stress (500 µM arsenite,
45 mins) before final lysis. The binding pattern of BRF2 and its mutants
with 14-3-3 on arsenite-induced oxidative stress [Figure 3.4:Panel C] remains
similar to that seen in untreated conditions [Figure 3.4: Panel B]. The BRF2-
S123,257A double mutant (henceforth termed as BRF2-AA) shows reduced
binding to 14-3-3 as compared to wildtype BRF2. The input amounts of 14-3-
3 were comparable in all samples. YFP-only control [Panel C, Lane 1] shows
no interaction with 14-3-3. This result shows that residues S123 and S257 of
BRF2 are responsible for 14-3-3 binding and this fact remains unchanged in
conditions of oxidative stress [Figure 3.4:Panel C, Lane 6] .
3.1.2.3 BRF2-S123,257A mutant shows reduced binding to 14-3-3 on
exposure to anisomycin-induced oxidative stress
The effects of arsenite on the cell occur mainly via production of reactive
oxygen species which has many side-effects apart from activating kinases. I
therefore tested anisomycin, a bacterial compound that more specifically ac-
tivates stress-activated MAPK subtypes. Moreover, serum starvation of cells
should downregulate kinase signalling and reduce background activity of other
kinases.
In these experiments, binding of 14-3-3 to BRF2 wildtype or the BRF2-AA mu-
tant was checked in presence of anisomycin. The experiment was divided into
four sets where transfected HEK293 cells were subjected to favourable growth
conditions, serum starvation (DMEM + 0.1% FCS, 2 hrs) or Anisomycin treat-
ment (10 µg/ml, 30 mins) or serum starvation + anisomycin treatment before
the final lysis. Figure 3.5 shows that on serum starvation and anisomycin
treatments, BRF2-AA can still bind significantly reduced amounts of 14-3-3
(Lanes 3,6,9,12) as compared to the wildtype BRF2 (Lanes 2,5,8,11). Taken
together, the experiments involving stress induced by arsenite or anisomycin
demonstrate that the kinase responsible for phosphorylating BRF2 and facil-
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itating 14-3-3 binding is constitutively expressed and that BRF2 interaction
with 14-3-3 is not dependent or affected on stress induction.
3.1.2.4 BRF2-S125,259P mutant shows reduced binding to 14-3-3
As seen in the optimal 14-3-3 binding motifs RSXpSXP and RXXXpSXP,
the presence of a proline at the +2 position was found to enhance 14-3-3
binding [217]. I generated a BRF2-S125,259P (henceforth termed as BRF2-
PP) mutant where the +2 positions for both the 14-3-3 binding sites were
changed to prolines [Figure 3.6: Panel A].
Subsequently, co-IP experiments were carried out in HEK293 cells to check for
the amount of 14-3-3 pulled down by the BRF2-PP mutant. Western blotting
shows no increase in 14-3-3 binding by this mutant. On the contrary, 14-3-
3 binding was lost in the presence of the two prolines [Figure 3.6: Panel B,
Lane 4] as compared to that pulled down by wildtype BRF2 [Figure 3.6: Panel
B, Lane 2]. In fact, the phenotype resembles that of the BRF2-AA mutant
(Lane 3). Incidentally, in the case of both S123 and S257, the +2 positions
are occupied by serines which could serve as alternative phosphorylation sites
allowing some residual 14-3-3 binding. Moreover, the sequence including S125
itself conforms to the criteria of an optimal 14-3-3 binding site (RSFSEN).
3.2 Regulation of AMD efficiency of BRF2
3.2.1 S123,257A mutations do not alter AMD efficiency of
BRF2
14-3-3 is known to modulate activities of its target proteins. It was shown that
in conditions of MK2 and PKB activation, 14-3-3 binds to and deactivates TTP
and BRF1, and reduces their AMD effiency. In derivatives of TTP and BRF1,
where serines in both the 14-3-3 binding sites of TTP and BRF1 were mutated
to alanines, 14-3-3 binding this prevented. The two mutants are locked in a
constitutively active form seen as enhanced AMD efficiencies. By the above
logic and seeing that BRF2 binds to 14-3-3, I hypothesized that 14-3-3 binding
might alter the AMD capacity of BRF2 as well.
To test this hypothesis, I performed doxycycline-chase mRNA decay assays
in HeLa cells using the ß-globin-ARE reporter mRNA system as was already
described in Figure 2.9: Panel B. In the experiment depicted in Figure 3.7, one
set consisted of favourable growth conditions (Panel A) and other set included
serum starvation (DMEM + 0.1% FCS, 2 hrs) and anisomycin treatment (10
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µg/ml, 30 mins) in order to resemble stress conditions in the cell (Panel B).
The BRF2-AA mutant did not seem to promote degradation of ß-globin-ARE
reporter mRNA significantly differently than BRF2 wildtype. The half-lives
were 0.8 hrs for BRF2 wildtype and 1.0 hrs for BRF2-AA in favourable growth
conditions (Panel A), and 2.4 hrs for BRF2 wildtype and 1.8 hrs for BRF2-
AA in conditions of serum starvation and anisomycin-induced stress (Panel
B). To allow for comparison, it was important to confirm that BRF2 wildtype
and BRF2-AA were expressed in equal amounts. Therefore, I withdrew an
additional sample for protein analysis and confirmed equal levels of expression
of both forms of BRF2 by western blotting [Figure 3.7:Panel C]. However, so
far the independent biological repeats of this experiment have been difficult
to interpret, owing mostly to the inconsistent levels of BRF2 and BRF2-AA
expression.
3.2.2 S125,259P mutations do not alter AMD efficiency of
BRF2
A similar mRNA decay assay was performed for the BRF2-PP mutant. This
mutant degraded reporter mRNA with an efficiency equal to that of BRF2
wildtype. Figure 3.8 shows the ß-globin-ARE reporter mRNA degradation
profile of BRF2 wildtype and that of the BRF2-PP. The graph below indicates
the quantification of the normalized signals from the northern blots. The ß-
globin-ARE reporter mRNA half-life in presence of the BRF2-PP mutant (0.9
hrs) is barely different to that in the presence of wildtype BRF2 (1.1 hrs).
3.3 Cellular localization of 14-3-3 binding site
mutants of BRF2
P bodies contain most enzymes for cytoplasmic mRNA degradation and are
thought to be sites of RNA decay. They also act as decision centres where the
fate of an mRNA is decided regarding decay, return to translation, or storage
in stress granules (reviewed in [246, 88]). It is possible that the localization of
BRF2 wildtype and its mutants would explain their AMD efficiencies.
To explore the subcellular localization of BRF2, HeLa cells were transfected
with HA-tagged versions of BRF2 wildtype, BRF2-AA, or BRF2-PP. Anti-HA
antibody was used to detect BRF2 proteins by immunoflorescence (IF). IF mi-
croscopy was carried out to gauge three parameters: a) nuclear vs cytoplasmic
abundance in presence or absence of stress, b) co-localization with P bodies,
and c) co-localization with stress granules. To get a better idea of differences
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between the three BRF2 constructs, 100 transfected cells were observed per
sample after randomizing the samples. P body and stress granule localizations
were quantified as percentage of transfected cells where HA-BRF2 showed co-
localization with the Rck and eIF3, respectively.
To check for P-body localization, the cells were left untreated but co-stained for
Rck, a P-body marker. P-bodies were counted in the untreated samples based
on co-localization of HA-BRF2 with Rck. The results for the co-localization of
BRF2 with P-body markers are shown in Figure 3.9. BRF2 showed a uniform
cytoplasmic staining. In addition, BRF2 and both its mutants clearly localized
to P bodies, determines as co-localization with Rck. As seen in the graphs,
BRF2wildtype, BRF2-AA, and BRF2-PP showed co-localization with P bodies
in 86%, 92%, and 93% of transfected cells, respectively. Thus, BRF2 wildtype
and mutants showed little difference between each other with regard to P-
body localization. Unlike TTP [193], a knockdown of Xrn1 was not required
to sequester BRF2 in P bodies. However, other studies claimed that Xrn1
knockdown was not required to localize TTP to the P bodies [63, 91].
To check for stress granule localization, the cells were subjected to oxidative
stress (500 µM arsenite, 45 mins) prior to fixing and were later co-stained
for eIF3, a stress granule marker [Figure 3.10]. Stress granules were counted
in the arsenite-treated samples based on co-localization of BRF2 with eIF3.
All the three constructs localized to stress granules, but with slightly different
efficiencies. Stress granule localization of BRF2 was rather weak, and a careful
observation was needed to ensure co-localization with eIF3. As seen in the
graphs, BRF2wildtype, BRF2-AA, and BRF2-PP showed co-localization with
stress granules in 72%, 85%, and 98% of the transfected cells, respectively.
Finally, for each transfected cell that was analysed, cellular localization was
categorized as nuclear (N), cytoplasmic (C), or as nuclear + cytoplasmic (N/C,
where traces of HA-BRF2 could be seen in the nucleus, but the overall abun-
dance remained in the cytoplasm). Figure 3.11: Panel A consists of a sum-
marizing graph of the localization studies upon induction of stress or without
it. On careful observation and quantification, I noticed a that BRF2-AA and
BFR2-PP showed higher nuclear presence, but a majority of the protein con-
tinued to remain in the cytoplasm in untreated conditions. In arsenite-induced
stress, BRF2 wildtype seemed to show a slight decrease in the nuclear fraction.
Such a change was not observed for the mutants. Phillips et al. [182] reported
nucleo-cytoplasmic shuttling of BFR2. I extended this study to include the
mutants of BFR2 [Figure 3.11: Panel B]. Transfected cells were exposed to
Leptomycin B (10 ng/ml, 2 hrs) which is a drug that binds to CRM-1 and pre-
vents proteins with an active nuclear export signal from being exported to the
cytoplasm [247]. In the IF experiments performed, I observed a strong nuclear
signal excluding the nucleolus for all three constructs of BRF2 with negligible
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amounts in the cytoplasm, indicating that BRF2 indeed shuttles between the
nucleus and the cytoplasm .
To summarize, there was no significant effect of the mutations on the P-body
localization of the BRF2 protein in its nucleo-cytoplasmic shuttling. Stress
granule localization appeared to increase in the BRF2 mutants as compared
to that in wildtype BRF2. However, this result needs to be treated with
caution. Firstly, the mutants seemed to show lesser expression. Secondly, due
to a slight increase in the nuclear localization, the cytoplasm could appear
more clarified and makes stress granules more easily visible.
3.4 DISCUSSION
BRF2 interacts with 14-3-3: I can confidently conclude from my experiments
that BRF2 binds to 14-3-3 protein. Simultaneous S123A and S257A muta-
tions abrogated the interaction between BRF2 and 14-3-3, since the mutated
sequences on BRF2 no longer conformed to the consensus binding sequences
of 14-3-3 [215, 216, 217]. It should be noted that individual mutations of these
sites did not hamper binding of BRF2 with 14-3-3. In many cases 14-3-3 is
known to bind as a dimer to two distinct residues of target proteins. Therefore,
binding is abrogated when both the binding sites for 14-3-3 in the interacting
proteins are simultaneously abolished. This has been exemplified in the TTP
family of proteins [194, 211] as well as other interactors of 14-3-3, for example,
DAF-16, the forkhead transcription factor [248]. Looking at the story from
the side of 14-3-3, it seems probable that 14-3-3 is active as a dimer and each
monomer binds to one site in the target protein. To analyse this, Powell et
al. [249] carried out a study which proved that 14-3-3 zeta was active only
as a dimer. A chemoattractant formyl-methionyl-leucyl-phenylalanine (fMLP)
stimulated the p38-MAPK pathway in neutrophils. Upon stimulation, 14-3-3
zeta was found to a target of MK2. MK2 phosphorylates S58 which lies on
the dimer-formation interface of 14-3-3 zeta. Phosphorylation of this S58 or a
phosphorylation-mimic mutation S58D prevents 14-3-3 dimer formation. The
thus-monomeric 14-3-3 is also incapable of binding to Raf-1, a known target
of 14-3-3, suggesting that dimer formation could be a pre-requisite for binding
to target ligands.
It is known that 14-3-3 isoforms homo-/hetero-dimerize while binding to target
proteins. In the co-IP assays of this study, I could see two closely-migrating
bands corresponding to 14-3-3. The higher molecular weight form could be 14-
3-3 epsilon, although it needs to be proved by using isoform-specific antibodies.
This could mean that at least two 14-3-3 isoforms are involved in binding to
BRF2. However, this finding needs to be treated with caution. Rittinger
45
3.4 DISCUSSION
et al. [217] performed elegant in vitro experiments which brought to light
the fact that isoform-specificity might be possible only in intact cells. They
incubated lysates of PC12 and 3T3/L1 cells with GST-tagged baits of seven
14-3-3 isoforms. A-raf, B-raf, c-Raf-1, BAD, and IRS-1 proteins, which exhibit
well-defined isoform specificity, were chosen as ligands. It was found that in
lysates the ligands lost their specificity towards 14-3-3 isoforms and all the
ligands bound to all 14-3-3 isoforms in vitro. The sole exception was B-raf
which failed to bind to 14-3-3 sigma and tau. This indicates that isoform
specificity in vivo might depend on cellular localization or transcriptional /
translational regulation of the isoforms. Thus, the two types of isoforms pulled
down in my experiments could well be a result of isoform non-specificity post
lysis of cells.
S123,257A mutations do not affect AMD efficiency of BRF2: In several ex-
periments, I noticed that BRF2-AA was expressed in lower amounts than the
wildtype BRF2 inspite of equal amounts of plasmid DNA being transfected.
This might indicate that the stability of the BRF2-AA mutant is different.
I performed cycloheximide chase assays to analyse this. Cycloheximide in-
hibits protein synthesis in the cell, thus the 0-hr timepoint is a reflection of
the steady-state levels for any protein inside the cell. Time-points collected
at 3-hr intervals over the next 9 hrs did not show any distinct difference in
the stability of the two proteins (data not shown). Subsequently, I tested var-
ious setups in which I transfected a fixed amount of BRF2 wildtype plasmid
and compared it to different amounts of BRF2-AA plasmid (data not shown).
Based on these experiments, I chose that DNA amounts that gave similar
expression levels of BRF2 wildtype and the mutant.
The long-standing idea was that 14-3-3 binds to the TTP family members
and inhibits their AMD capacity as was proven for TTP and BRF1. Hence,
mutants of TTP and BRF1 to which 14-3-3 failed to bind showed higher AMD
activity. However, my results stand in contradiction to this idea. In the given
experimental conditions, 14-3-3 binding did not alter AMD efficiency of BRF2.
In doxycycline-chase mRNA decay assays, it was seen that BRF2 wildtype and
its 14-3-3 binding site mutants degrade ARE-containing reporter mRNA with
comparable efficiencies in .
This is similar to the study by Marchese et al. [196] which spoke against
involvement of 14-3-3 in controlling TTP-induced deadenylation. The authors
carried out in vitro deadenaylation assays that included wildtype TTP or its
mutant TTP-S52,178A which does not bind to 14-3-3. The results obtained
clearly showed that the rates of TTP-induced deadenylation were different for
both the constructs of TTP. This difference was dependent on phosphorylation
of TTP at S52 and S178; however, independent of 14-3-3 binding. The same
was further confirmed by using R18 and dipofein which are high affinity 14-3-3
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antagonists that cause nearly complete inhibition of 14-3-3 binding to target
proteins. In in vitro assays, the deadenylation activity of TTP was unchanged
in the presence of these 14-3-3 inhibitors confirming that 14-3-3 did not play a
role in inhibition of TTP-induced deadenylation. Eventually the inhibition was
attributed to MK2 kinase which phosphorylates TTP and hampers recruitment
of the Caf1a deadenylase. However, a caveat is that these data were based on
in vitro deadenaylation assays carried out over a period of only the initial 30
mins. This approach could miss the later events in the degradation process.
Stoecklin et al. [194] had claimed the contrary that 14-3-3 takes an active part
in inhibiting AMD activity of TTP and these assays monitored ARE-mRNA
decay inside cells. As for BFR1, overexpression of active forms of PKBA kinase
[211] and MK2 kinase [233] have been shown to increase 14-3-3 binding and
inhibit ARE-mRNA degradation. In conclusion, my study testifies that in the
given experimental conditions, AMD activity of BRF2 is regulated differently
than the other TTP family members.
Since all experiments in my study are performed in either HEK293 or HeLa
cells, they could miss out on some cell-type specific cues. Earlier reports have
established that 14-3-3 isoforms can be cell-type specific e.g. 14-3-3 eta forms
with two different 5’ UTRs which is expressed in hematopoietic cells [250], 14-
3-3 sigma which is expressed only on DNA damage in a p53-dependent manner
to bring about cell-cycle arrest [251]. Coincidentally, both the above examples
cited would be of future interest in this project, since BRF2 is involved in
hematopoietic development [235] and over-expression of BRF2 activates the
DNA damage response and apoptosis in a p53-dependent manner [252]. The
experiments in this study could be repeated in cells of hematopoietic origin.
BRF2 readily localizes to P bodies and to stress granules induced by oxida-
tive stress: For this part of the study, I purposefully chose cells which ex-
pressed low to medium levels of transfected BRF2, since the cells express-
ing high amounts of the protein had a stretched-out appearance resembling
apoptotic cells. Moreover, high signal intensities made it difficult to observe
co-localization. I noticed a difference between BFR2 and other TTP family
members with regard to P-body and stress granule localization. Franks et
al. [193] saw that only 13% of cells transfected with TTP showed presence of
TTP in P bodies. On knockdown of Xrn1 i.e. when ARE-mRNA degradation
is halted midway, presence of TTP in P bodies drastically increased to 90%.
This could indicate that TTP localizes to P bodies only transiently. The same
study claimed that BRF1 showed a similar effect. My study proved that BRF2
spontaneously localized to P bodies in 86% cells transfected with BRF2. For
the 14-3-3 binding mutants of BRF2, these values were >90%. The difference
in P-body localization could be attributed to a poly-Q stretch present in the
C-terminus of BFR2, something that is absent in both TTP and BRF1. Poly
Q/N stretches are a feature common to many P-body proteins, and out of
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twenty P-body proteins analysed, all were shown to have significantly above-
average Q/N contents. These stretches have been suggested to aid aggregation
of these proteins [99]. Whether P-body localization of BRF2 is prompted by
the Q-rich domain can be proved by employing a deletion mutant of BRF2
lacking the Q repeats.
As for stress granule localization, Stoeckin et al. demonstrated that MK2-
induced TTP:14-3-3 complexes failed to localize to the stress granules. TTP
and its 14-3-3 binding mutant were recruited to arsenite-induced stress granules
at different efficiencies (TTPwt, 0.5%; TTP-S52,178A, 59%). It was concluded
that binding to 14-3-3 prevents localization of TTP to stress granules [194].
Contrary to these observations, I found that BRF2 wildtype and its 14-3-3
binding mutants readily localized to arsenite-induced stress granules. In fact,
BRF2-AA and BRF2-PP mutants showed slightly increased localization to
oxidative stress-induced stress granules.
14-3-3 affects nucleo-cytoplasmic localization of BRF2 minimally: In my stud-
ies, I observed that on exposure to oxidative stress, the slight presence of BRF2
in the nucleus decreased further, indicating export of BRF2 to the cytoplasm.
Such a nucleo-cytoplasmic shift was not distinctly seen for BRF2-AA and
BRF2-PP. 14-3-3 binding has been shown to alter the cellular localization of
target proteins (reviewed in [253]). In a more specific example, 14-3-3 binding
causes TTP to shift to the cytoplasm. This is thought to facilitate engaging
in AMD which is a cytoplasmic process [213]. In BRF2, now knowing the
location of the 14-3-3 binding sites, it is possible that binding to 14-3-3 could
mask the NLS which is located in the zinc finger region, and thus promote cy-
toplasmic localization of the protein. By this logic, mutants that fail to bind
to 14-3-3 would have an exposed NLS and hence would show their presence in
the nucleus as well, which is seen in my study. On stress induction, increase in
14-3-3 binding to BRF2 possibly causes masking of NLS of BRF2, and 14-3-3
dependent export to the cytoplasm. However, if 14-3-3 binding was the sole
determinant of cytoplasmic localization, the mutants which fail to bind to 14-
3-3 would show a strong nuclear and minimal cytoplasmic localization which
was not observed here. Some more deciding factors for the cytoplasmic local-
ization of BRF2 could be the NES in its C-terminus or interacting proteins of
BRF2.
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Figure 3.4: BRF2-S123,257A mutant shows reduced binding to 14-3-3. Panel
A: Summary of mutations affecting putative 14-3-3 binding sites in BRF2 used in this
study. Panels B and C: HEK293 cells were transiently transfected with plasmids express-
ing YFP-BRF2 wildtype or YFP-tagged 14-3-3 binding site mutants of BRF2. YFP-only
is included as a control. Cytoplasmic lysates were prepared 24 hrs after transfection.
Panel B: Untreated samples. Panel C: Transfected cells treated with 500 µM arsenite for
45 mins before final lysis. Lysis buffer included inhibitors to proteases and phosphatases.
Co-IP experiments were performed as mentioned previously in Figure 3.2 legend.
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Figure 3.5: BRF2-AA mutant shows reduced binding to 14-3-3 in presence of
serum and anisomycin. HEK293 cells were transiently transfected with plasmids en-
coding YFP-only, YFP-BRF2, or YFP-BRF2-AA as indicated in the figure. Cytoplasmic
lysates were prepared 24 hrs after transfection. Before lysis, four combinations of treat-
ments were performed. the treatments were as follows, Lanes 1-3: no serum starvation,
no anisomycin; Lanes 4-6: no serum starvation, anisomycin; Lanes 7-9: serum starvation,
no anisomycin, and Lanes 10-12: serum starvation, anisomycin. Co-IP experiments were
performed as mentioned previously in Figure 3.2 legend.
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Figure 3.6: BRF2-S125,259P mutant shows reduced binding to 14-3-3. Panel
A: BRF2-S125,259A mutant. Panel B: HEK293 cells were transiently transfected with
plasmids encoding YFP-only, YFP-BRF2, YFP-BRF2-AA, or YFP-BRF2-PP, as indi-
cated in the figure. Cytoplasmic lysates were prepared 24 hrs after transfection. Co-IP
experiments were performed as mentioned previously in Figure 3.2 legend.
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Figure 3.7: AMD efficiency of BRF2-AA mutant as compared to BRF2 wild-
type. A Tet-off system was employed. HeLa cells were transfected with empty-vector,
or plasmids encoding HA-BRF2, or HA-BRF2-AA as indicated in the figure. Panel A:
Favourable growth conditions (DMEM + 10% FCS). Panel B: serum starvation (DMEM
+ 0.1% FCS, 2 hrs) and anisomycin treatment (10 µg/ml, 30 mins) before the 0-hr time-
points of the doxycycline -chase mRNA decay assays which were performed over a
period of 3 hrs. Northern blotting RNA probes used were specific for ß-globin reporter
gene and nucleolin as loading control. Reporter mRNA levels were normalized to nucle-
olin mRNA levels. 0-hr timepoint which represents steady state levels of reporter mRNA
was set to 100% and the other values were compared to that. mRNA levels plotted on
the graph and the half-lives are a mean ± s.e.m. of three independent biological repeats.
Panel C: Samples of transfected cells were processed by western blotting and probed with
mouse monoclonal anti-HA antibody to detect BRF2 protein.
52
Regulation of BRF2 activity
Figure 3.8: BRF2-PP mutant degrades ARE-containing mRNAs with equal
efficiency as wildtype BRF2. A Tet-off system was employed. HeLa cells were trans-
fected with empty-vector, or plasmids encoding HA-BRF2, HA-BRF2-AA, or HA-BRF2-
PP as indicated in the figure. doxycycline -chase mRNA decay assays were performed
over a period of 3 hrs. Northern blotting was carried out as mentioned in Figure 3.7
legend.
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Figure 3.9: BRF2 wildtype and its 14-3-3 binding site mutants localize to P
bodies at comparable efficiencies. HeLa cells were transfected with plasmids encod-
ing HA-BRF2 wildtype, HA-BRF2-AA, or HA-BRF2-PP. Cells were stained with mouse
monoclonal anti-HA antibody to visualise BRF2 protein, and were co-stained for Rck
protein, a P body marker. The graph depicts percentage of transfected cells in which
BRF2 and its mutants were recruited to P bodies.
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Figure 3.10: BRF2 wildtype and its 14-3-3 binding site mutants localize to
oxidative stress-induced stress granules at varying efficiencies. HeLa cells were
transfected with plasmids encoding HA-BRF2 wildtype, HA-BRF2-AA, or HA-BRF2-PP.
Cells were exposed to oxidative stess (500 µM arsenite, 45 mins) prior to fixing, stained
with mouse monoclonal anti-HA antibody to visualise BRF2 protein, and co-stained for
eIF3 protein, a marker for oxidative stress-induced stress granules. The graph depicts
percentage of transfected cells in which BRF2 and its mutants were recruited to stress
granules.
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Figure 3.11: Cellular localization of BRF2 wildtype and its 14-3-3 binding site
mutants. HeLa cells were transfected with plasmids encoding HA-BRF2 wildtype, HA-
BRF2-AA, or HA-BRF2-PP. Cells were stained with mouse monoclonal anti-HA antibody
to visualise BRF2 protein in samples in all the panels below. PanelA: For each transfected
cell that was observed, cellular localization was categorized as nuclear (N), cytoplasmic
(C), or as nuclear + cytoplasmic (N/C, where traces of protein could be seen in the
nucleus, but overall abundance remained in the cytoplasm). Graph depicts percentage of
transfected cells showing BRF2 localization as N or N/C in untreated or arsenite-treated
samples. IF images of examples of C and N/C localization are included for reference.
Panel B: Cells were exposed to Leptomycin B (10 ng/ml, 2 hrs) prior to fixing. Images
from corresponding untreated cells are reproduced from Figure 3.9.
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4 Kinase(s) involved in
phosphorylating BRF2
In the previous co-IP experiments, I demonstrated that the phosphorylation
status at S123 and S257 of BRF2 determines its binding to 14-3-3. The ki-
nase(s) involved in BRF2 phosphorylation are as yet unknown. The results of
the previous experiments indicated that I should screen kinases which would
target phospho-serines in the BRF2 sequence. I analysed the BRF2 protein
sequence (P47974 from UniProtKB/Swiss-Prot database) using the Phospho-
Motif Finder database published in [254]. The sequence was queried against
the known substrate sequence motifs for various protein serine/threonine ki-
nases which led to a list of >300 substrate sequence motifs in BRF2. These
results included a significant number of redundant hits. I next used the Phos-
phoNET database (PhosphoNET is an online open-access resource developed
by Kinexus Bioinformatics Corporation, Canada) which still predicted >30
possible phosphoserines in BRF2 and multiple kinases corresponding to each
serine-containing sequence stretch.
4.1 PKBA and MK2 kinases may affect BRF2
binding to 14-3-3
Since the number of prospective kinases was overwhelming, I decided to fol-
low an approach of analogy between BRF2 and other members of the TTP
family of proteins, namely, BRF1 and TTP. It is known from the literature
that 14-3-3 binding sites of TTP are phosphorylated by MK2 kinase [194]
and those of BRF1 by the kinases PKBA [232] and MK2 [233]. With this, I
proceeded with checking the effect of these two enzymes first. Constitutively-
active forms and inactive forms of PKBA and MK2 kinases were co-transfected
during co-IP experiments. The idea was to alter the levels of phosphorylation
of over-expressed BRF2 proteins by co-overexpressing active/inactive forms
of the kinases. If these kinases were involved in the process, active forms of
the kinase should enhance BRF2 phosphorylation and 14-3-3 binding. The
inactive forms should compete with their endogenous active counterparts and
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reduce BRF2 phosphorylation and 14-3-3 binding. If the kinases were not in-
volved, the extent of 14-3-3 binding would remain unaltered. The modified
co-IP protocol included serum starvation (DMEM + 0.1% FCS, different du-
rations ranging from 6-24 hrs were tried). Serum starvation was used to ensure
downregulation of kinase signalling to bring down the steady-state phosphory-
lation levels inside the cell. The activity of the studied kinases would thus be
monitored without interference from other kinases. No difference in BRF2:14-
3-3 binding was observed between normal growth conditions and conditions of
serum starvation.
As seen in Figure 4.1, YFP-BRF2 is over-expressed in all sets except the
empty-vector control. Co-IP experiments were carried out using GFP-binder
beads as described before. Additionally, input fractions were probed with anti-
MK2 antibody to ensure that equal amounts of active and inactive MK2 was
expressed. When compared with the levels of 14-3-3 pulled down by YFP-
BRF2 alone (Lane 2), the following observations were made. a) Lane 3: YFP-
BRF2 + MK2-T205,317E (constitutively active mutant of MK2, henceforth
termed as MK2-EE) pulls down more 14-3-3, b) Lane 4 : YFP-BRF2 + MK2-
K76R (kinase-dead mutant of MK2, henceforth termed as MK2-KR) pulled
down reduced amounts 14-3-3, c) Lane 6: YFP-BRF2 + m/p PKBA (con-
stitutively active mutant of PKBA, henceforth termed as PKB) pulled down
less 14-3-3, and d) Lane 7 : YFP-BRF2 + PKBA-K179A (inactive mutant of
PKBA, henceforth termed as PKBA-KA) pulls down reduced amounts 14-3-3.
These data suggest that MK2 is involved in phosphorylating BRF2, hence the
inactive kinase reduces BRF2 phosphorylation and impedes its binding with
14-3-3. In the case of active PKBA, lesser 14-3-3 appears to be pulled down;
however, the amount of precipitated YFP-BRF2 is also lower than in other
lanes. Thus the effect of PKBA on BRF2 was not conclusive. Lanes 5 and 8
involved chemical inhibitors of the p38 and PI3K pathways, respectively, and
will be discussed in the next section.
4.2 Effect of inhibitors of the PKB and MK2
kinase pathways
In the previous experiment, I saw that PKB and MK2 both might be in-
volved in phosphorylating BRF2. This strategy was prone to artifacts of over-
expression. An alternative test would be to suppress the activity of these
kinases by addition of specific chemical inhibitors. I made use of inhibitors
to kinases that are upstream to MK2 and PKBA. I hence attempted to in-
hibit PKB using Wortmanin which inhibits the upstream PI-3Kinase [255],
and MK2 using SB202190 which inhibits the upstream p38 kinase [256].
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Preliminary experiments involving these inhibitors were performed in normal
growth conditions or under serum starvation and showed no difference in 14-3-
3 binding to BRF2 [Figure 4.1: Lanes 4,8, and data not shown]. Henceforth, I
treated the cells with anisomycin to additionally activate the stress response,
increase the requirement for stress-responsive kinases, so that the cells would
respond to the inhibitors more drastically. If the PKBA or MK2 kinase was
essential for BRF2 phosphorylation, the corresponding inhibitor would cause
a reduction in BRF2 phosphorylation and reduce 14-3-3 binding to BRF2. In
this experiment, I also included a set where I used both inhibitors together to
achieve a tighter inhibition of BRF2 phosphorylation in case both the kinases
were redundant in action.
Figure 4.2 depicts the effect of the inhibitors in combination with anisomycin
treatment. The presence of inhibitors did not cause any reduction in BRF2
binding to 14-3-3 (Lane 3 for p38 inhibitor, Lane 4 for PI3-K inhibitor, Lane
5 for both inhibitors in unison). Here it was important to confirm whether
the inhibitors had worked. The levels of active PKB were checked by using
antibodies against phospho-PKB kinase, which did not work due to technical
problems in western blotting experiments. I checked for levels of active MK2
by probing the input fractions with a anti-phosphoT334-MK2 antibody. All
the lanes, including the ones with SB202190 inhibitor, had the same levels
of active MK2 kinase, shown by phosphorylation of T334 residue of MK2,
which is a site phosphorylated by p38 kinase. This suggests that either the
inhibitor to p38 kinase had not worked hence the MK2 kinase was still being
phosphorylated or the inhibitor was not being taken up by the cells. I decided
to follow the more direct and specific siRNA approach to silence the kinases.
4.3 Effect of siRNA-mediated knockdown of MK2
Co-expression of both active and inactive forms of PKBA kinase disturbed the
expression of BRF2 and BRF2 levels were mostly decreased compared to those
in the other sets. This made interpretation of the experiments very difficult.
In the experiments hereforth, I focussed first on MK2 kinase. I used a siRNA
against MK2 kinase, as mentioned in [214]. As seen in Figure 4.3: Panel B,
I transfected siRNA-MK2 twice over a period of four days. siRNA-D0 was
included in the experiment as a control. siRNA-MK2 effectively reduced the
levels of MK2 to 22.4 % (Panel B, Lane 2). However, samples in all lanes
had the almost equal levels of activated MK2, shown by phosphorylation of
T334 residue of MK2, which is a site phosphorylated by p38 kinase Figure 4.3:
Lanes 1-4.
The downregulation of MK2 failed to cause any alteration in 14-3-3 binding to
BRF2 (Panel A, Lane 2) compared to that in presence of control siRNA-D0
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(Panel A, Lane 4). One reason for this could be that the remaining level of
MK2 is sufficient for phosphorylating the BRF2 present in the cell. Moreover,
downregulation of MK2 kinase might be compensated by other kinases in the
cell. In conclusion, the inhibitor studies and the siRNA knockdown of MK2
failed to confirm that MK2 kinase plays a role in BRF2 phosphorylation.
4.4 MK2 does not alter AMD-efficiency of BRF2
The final goal of studying involvement of MK2 in phosphorylating BRF2 was to
know if BRF2 phosphorylation and binding to 14-3-3 alters the AMD efficiency
of BRF2. I hence performed mRNA decay assays using globin-ARE reporter
mRNA in the presence of BRF2 and co-expressed MK2-EE or MK2-KR. Serum
starvation conditions (DMEM + 0.1% FCS, 12 hrs) were used to downregulate
basal kinases activity and ensure that the effect seen, if any, was due to the
over-expressed MK2 kinase versions.
I performed two sets of doxycycline -chase mRNA decay experiments as seen
in Figure 4.4. Sets seen in Panel A were performed under normal growth
conditions, and those in Panel B under serum starvation conditions. In each
set, globin-ARE mRNA decay in the presence of BRF2 plus empty vector
was taken as a reference. I found that there was no detectable effect of over-
expression of MK2 kinase active or inactive forms on AMD brought about by
BRF2, since the reporter mRNA half-lives in presence of BFR2 + MK2-EE
or BFR2 + MK2-KR were similar to those in presence of BRF2 alone. Values
from three independent biological repeats of this experiment were compiled and
plotted in the graphs beside the northern blots and the half-lives are given as
mean ± s.e.m. Panel C shows a western blot to ensure equal expression of the
two MK2 forms.
4.5 DISCUSSION
p38 MAP kinase and activated downstream kinases have been shown to antag-
onize AMD and stabilize ARE-containing mRNA. mRNAs of IL-6 and IL-8 are
stabilized by MEKK-1, and that of IL-8 by MK2 [257]. MK2 controls TNFA
and IL-6 biosynthesis albeit by different mechanisms [203, 204]. Kinases af-
fect stability of mRNAs indirectly via control of RNA binding proteins. PKB
[211] and MK2 [233] are known to independently control AMD efficiency of
BRF1. MK2 also determines the stability of TNFA mRNA via modulation of
the expression and activity of TTP [202].
I could consistently see in co-IP experiments that co-expressing MK2-KR re-
duced binding of 14-3-3 to BRF2, while co-expressing MK2-EE showed more
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or less equal levels of 14-3-3 binding to BRF2 in comparison to the BRF2-
only transfected controls [Figure 4.1]. Drawing analogy with other TTP family
members, I hypothesized that MK2-EE over-expression would hyper-phosphorylate
BRF2, enhance 14-3-3 binding, and cause a concommitant decrease in the
AMD efficiency of BRF2. To this end, I checked if over-expression of the MK2
active or inactive forms affected the ability of BRF2 to accelerate ß-globin-
ARE reporter mRNA degradation. I could see no significant difference in the
RNA decay patterns in presence and absence of MK2. This implies that in the
given experimental conditions MK2 did not modulate AMD efficiency of BRF2.
This was rather contradictory to regulation of other TTP family members by
MK2, but nevertheless an important finding of this study.
It is possibile that phosphorylation of a substrate by MK2 may not produce
any discernible change in the function of the substrate. One such example
is that of a structural protein, Vimentin, which is involved in intermediate
filament assembly [258]. Vimentin is a substrate for multiple kinases and in
most cases phosphorylation causes structural changes. However, it was shown
that MK2 phosphorylated recombinant Vimentin protein on residues S38, S50,
S55, and S82 but this did not produce any drastic structural changes. Vimentin
maintained its filament-forming activity despite being phosphorylated by MK2,
while phosphorylation by protein kinase A (PKA) caused a loss of filament
structure [259].
One more observation was that the MK2 active and inactive mutants produced
the same effect with regard to ß-globin-ARE mRNA degradation. The mutants
of MK2 used are the constitutively active mutant, MK2-T205,317E; and the
kinase-dead mutant, MK2-K76R. In the active MK2 form, the two given thre-
onines are mutated to glutamate to mimic the negative charge of phosphates
otherwise needed to activate MK2 [260]. The inactive form, MK2-K76R, in-
volves a mutation of the conserved lysine in the ATP-binding subdomain II to
arginine. This confers upon it the qualities of a kinase-dead negative interfer-
ring mutant [257]. In the ideal situation, the mutant lacking kinase activity
should translate into some difference in activity between the two MK2 forms.
The reasons for both the mutants behaving in a similar fashion with regard to
ß-globin-ARE mRNA degradation could be: a) 14-3-3 acts as a scaffold pro-
tein between BRF2 and MK2, and MK2 acts merely as a platform onto which
further complexes load/are prevented from loading, b) formation of BRF2/14-
3-3/MK2 complex does not hinder downstream mRNA degradation processes,
e.g. blocking of Caf1a recruitment, as shown for TTP in [196] because binding
regions for different complexes are mutually exclusive. Both of the above could
need only the physical presence of MK2, irrespective of its catalytic activity.
Alternatively, c) MK2 may not play any role in regulating BRF2-mediated
AMD, but BRF2 phosphorylation might be brought about by a constitutive
kinase which performs its function despite the presence of over-expressed MK2
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active or inactive forms.
In my study, the only parameter I have questioned so far was AMD efficiency
of BRF2. The change brought about in the cell due to BRF2:14-3-3 complex
formation might manifest in alternate ways, e.g., MK2 controls TNFA [203]
and BRF1 controls VEGF [229] at the level of translation. On the basis of
these studies, it could be possible that MK2 action on BRF2 may alter the
translation rate of ARE-containing target mRNA.
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Figure 4.1: MK2 and PKBA kinases may affect 14-3-3 binding to BRF2.
HEK293 cells were transiently transfected with plasmids encoding YFP-only,
YFP-BRF2, YFP-BRF2+MK2-EE (active), YFP-BRF2+MK2-KR (inactive), YFP-
BRF2+m/pPKBA (active), or YFP-BRF2+PKBA-KA (inactive) as indicated in the fig-
ure. Cytoplasmic lysates were prepared 24 hrs after transfection. Co-IP experiments were
performed as mentioned previously in Figure 3.2 legend. Additionally, the input fractions
were probed with anti-myc (MK2) and anti-PKBA antibodies to ensure expression of equal
amounts of kinases. Information on inhibitors to kinases in the later section.
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Figure 4.2: Effect of chemical inhibitors to MK2 and PKBA kinase pathways
on 14-3-3 binding to BRF2. HEK293 cells were transiently transfected with plas-
mid encoding YFP-BRF2. 1 hr before lysis, 10 µg/ml anisomycin was added to the
medium in combination with inhibitors to MK2 or PKBA kinases: 10 µM SB202190 (p38
MAPK inhibitor) against MK2, 15 µM Wortmanin (PI3-Kinase inhibitor) against PKBA.
YFP-only was indcluded as a control. Cytoplasmic lysates were prepared 24 hrs after
transfection. Co-IP experiments were performed as mentioned previously in Figure 3.2
legend. Additionally, the input fractions were probed with anti-phosphoMK2-T334, a
residue phosphorylated by p38 kinase, to check for the effect of SB202190 inhibitor.
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Figure 4.3: siRNA knockdown of MK2 does not have any effect on 14-3-3
binding to BRF2. Panel A: Co-IP experiments were carried out after transfecting
siRNA-MK2 or siRNA-D0 twice over a period of 4 days. Plasmids encoding YFP-BRF2
or YFP-only control siRNA-MK2 were included in the second transfection. co-IP exper-
iments were performed as mentioned previously. Co-IP experiments were performed as
mentioned previously in Figure 3.2 legend. Additionally, the input fractions were probed
with anti-phospho MK2-T334 to check for the remainder active form of MK2. Panel
B: Samples were withdrawn 24 hrs after the first transfection, i.e. Day-2 (T-1), and 24
hrs after the second transfection, i.e. Day 4 (T-2), and subjected to western blotting to
determine the efficiency of MK2 knockdown. MK2 levels from the western blot after the
second transfection from samples treated with siRNA-MK2 or siRNA-D0 were normalized
to an unidentified band each from the ponceau staining.
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Figure 4.4: MK2 does not modulate AMD efficiency of BRF2. A Tet-off system
was employed. HeLa cells were transfected with empty-vector, or plasmids encoding HA-
BRF2, HA-BRF2+MK2-EE (active), or HA-BRF2+MK2-KR (inactive) as indicated in
the figure. Panel A, untreated cells; Panel B, cells subjected to serum starvation (DMEM
+ 0.1% FCS, 12 hrs) before final lysis. doxycycline -chase mRNA decay assays were
performed over a period of 3 hrs. Northern blotting and quantification of results was
carried out as mentioned in Figure 3.7 legend. Panel C: Samples of transfected cells were
subjected to western blotting and probed with anti-MK2 antibody.
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5 BRF2 interacts with the
deadenylation machinery
5.1 BRF2 interacts with Not1 and Caf1a
Having established that phosphorylation of BRF2 and the consequent 14-3-3
binding does not affect the functionality of BRF2 regarding AMD, I decided to
explore for additional interactors of BRF2 to reveal other layers of regulation.
Previous studies have unearthed links between the deadenylation apparatus
and the TTP family members. TTP interacts with Not1, Caf1a via Not1
[198], and Ccr4 [179]. BRF1 was also shown to interact with Not1 (unpublished
observation, Heike Sandler) and Ccr4 [179]. Moreover, Lai et al. [197] provided
evidence that BRF2 was capable of initiating mRNA deadenylation. Keeping
in mind the above findings, I decided to check if BRF2 physically interacts
with members of the deadenylation apparatus in the cell.
To this effect, I performed co-IP experiments in HEK293 cells where HA-BRF2
was co-expressed with Not1 or Caf1a. Not1 protein spans 2376 amino acids and
has been known to pose problems with regard to over-expression. Having ex-
perienced this difficulty myself in the initial experiments, I chose to work with
YFP-Not1(aa1330-1601), a fragment of Not1 which is known to interact effi-
ciently with TTP [198]. YFP-tagged versions of the deadenylation machinery
components were used as a bait and HA-BRF2 was pulled down employing the
GFP-binder approach. As seen in Figure 5.1, HA-BRF2 interacts with Not1
(Lane 2) and Caf1a (Lane 3). This strongly hints at interactions between
BRF2 and the deadenylation apparatus.
5.2 DISCUSSION
PolyA tails have enjoyed an important role in AMD. TTP, and to a certain
extent BRF1, have been previously studied in terms of their abilities to in-
teract with the cellular deadenylation machinery [201, 179, 261, 198]. The
deadenylase PARN has already been shown to play a role in deadenylation of
ARE-containing mRNAs in presence of BRF2 [197]. In my study, I tried to
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see if BRF2 also interacts with the CCR4-Not complex, the major cytoplasmic
deadenylation complex in metazoans. In this multi-component machinery (re-
viewed in [262, 23]), Not1 is the scaffold protein that holds together multiple
components of the deadenylation complex. Not1 interacts with the C-terminus
of TTP. Caf1a is recruited to TTP indirectly via Not1 [198]. The domain of
interaction in BRF1 is as yet unmapped. A functional TTP-deadenylation
complex thus forms which progressively shortens the polyA tail, wherein TTP
provides mRNA selectivity. Figure 5.1 shows that BRF2 interacts with the
Not1 fragment and Caf1a. Unless the remaining portion of the Not1 acts in-
hibitory in any way, it seems possible that BRF2 could be the link between
the deadenylation machinery and the ARE-containing mRNA which is des-
tined for degradation. This finding needs to be confirmed with more repeats,
with full-length Not1, and if possible with the endogenous deadenylating pro-
teins. Moreover, it remains to be determined whether these interactions are
direct.
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Figure 5.1: BRF2 interacts with the deadenylation machinery. Co-IP experi-
ments were carried out using HEK293 cells where plasmids encoding YFP-Not1 or YFP-
Caf1a were transfected along with HA-BRF2. Plasmid pMT2 was co-transfected to im-
prove expression especially of Not1. Cytoplasmic lysates were prepared 24 hrs after
transfection. Co-IP experiments were performed as mentioned previously in Figure 3.2
legend. Western blotting analyses were carried out using an anti-GFP antibody to de-
tect the YFP-Not1 and YFP-Caf1a, and a mouse monoclonal anti-HA antibody to detect
BRF2.
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6 Truncation mutants of BRF2
BRF2 is a relatively new player on the AMD scene and little is known about
its functions and domain structure. That BRF2 possesses two C3H-type zinc
fingers is well-established [263]. My study suggested the presence of at least
two 14-3-3 binding sites. Bioinformatical approaches to predict the domain
structure of BRF2 reveal rather limited information. Hence, I created trunca-
tion mutants of BRF2 [Figure 6.1] in order to find the minimal active region of
BRF2 with regard to AMD and the contribution of other regions in regulating
this activity.
Figure 6.1: Schematic representation of truncation mutants of BRF2. PCR-
based cloning was carried out to generate the following truncation mutants: 1) aa1-
275 (NTD+RBD), 2) BRF2:aa97-275 (RBD), 3) BRF2:aa97-494 (RBD+CTD), and 4)
BRF2:aa97-442 (RBD+CTD lacking the Nuclear export signal, NES).
BRF2 protein can be divided into three domains: 1) the N-terminal domain
(NTD), 2) the central domain which consisted of the two 14-3-3 binding sites
(this study) and the two C8C5C3H zinc-finger motifs (RBD, RNA-binding
domain), and 3) the C-terminal domain (CTD). PCR-based cloning was car-
ried out to generate the following truncation mutants: aa1-275 (NTD+RBD),
aa97-275 (RBD), aa97-494 (RBD+CTD), and aa97-442 (RBD+CTD lacking
the Nuclear export signal, NES). Of these four clonings, the first two were
successful and the remainder two are in progress.
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6.1 Cellular localization of truncated versions of
BRF2
Immunoflorescence experiments were carried out to check the cellular local-
ization of HA-tagged NTD+RBD and RBD alone. Two sets of cells were
processed and the results are as seen in Figure 6.2. The first set of cells (Panel
A) were co-stained for the Rck protein, a marker for P bodies. BRF2:aa1-275
bears a predominantly-nuclear localization with low amounts seen in the cyto-
plasm, whereas BRF2:aa97-275 shows an even stronger nuclear signal with only
minimal amounts seen in the cytoplasm. Both forms of BRF2 were recruited
to P bodies seen as co-localization with Rck; BRF2:aa97-275 was recruited at a
lesser frequency which could be because of the already less amounts present in
the cytoplasm. Leptomycin treatment (10 ng/ml, 2 hrs) confined the protein to
the nucleus in cases of both the constructs. Cells seen in Panel B were exposed
to oxidative stress (500 µM arsenite, 45 mins) to induce stress-granule forma-
tion, and co-stained for eIF3 which is a stress granule marker. Under these
conditions, BRF2:aa1-275 displayed a striking change in cellular localization.
In all the transfected cells observed, the protein shifted from a predominantly-
nuclear to a strongly-cytoplasmic localization. Interestingly, BRF2:aa97-275
remained mostly nuclear and there appeared to be a faint signal from the cyto-
plasm as against full-length BRF2 which is predominantly cytoplasmic. Both
these forms of BRF2 were recruited to stress granules seen as co-localization
with eIF3. Co-localization with stress granules was more readily visualized in
these truncation mutants as compared to that in wildtype due to the highly-
clarified cytoplasm. For the sake of comparison, Panel A and B include BRF2
wildtype controls reproduced from Figure 3.9 and Figure 3.10, respectively.
6.2 AMD-efficiency of truncated mutants of
BRF2
doxycycline -chase RNA decay assays were performed with the truncated pro-
teins as described in the previous sections. Figure 6.3: Panel A shows the
results of the single RNA decay experiment performed till date employing the
constructs, BRF2:aa1-275 and BRF2:aa97-275. Similar to the full-length pro-
tein, both the constructs were found be capable of accelerating ARE-containing
reporter mRNA degradation as seen from the half-lives of the ß-globin-ARE
reporter mRNA. Panel B is a graphical representation of northern blots and
Panel C is to ensure comparable levels of expression of the constructs.
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6.3 DISCUSSION
BRF2:aa1-275 and BRF2:aa97-275 show a predominantly-nuclear localization,
as against a cytoplasmic localization for BRF2 wildtype. This could be because
both these truncation constructs are devoid of the NES in the C-terminus of
the full-length protein, but still bear the NLS which is in the zinc finger domain
(Figure 3.4). The NLS, which is embedded in the two zinc fingers could render
the truncated proteins nuclear [182]. Previous studies by Phillips et al. showed
that deletion or substitution mutants of TTP and BRF1 NES sequences led
to nuclear localization [182]. A I373fsX91 frameshift mutation in BRF2 was
observed in a patient suffering from acute myeloid leukemia that caused loss
of the C-terminus of BRF2 and thus loss of the known NES. However, this
mutant BRF2 protein localized to the cytoplasm [236].
Both the BRF2 truncation constructs are capable of promoting ß-globin-ARE
reporter mRNA degradation, and both are present in P bodies. However, since
the RBD alone (aa97-275) is sufficient to bring about RNA decay, this could
mean that the NTD and the CTD have more of a regulatory role with regard
to RNA decay activity. In cells subjected to arsenite-induced oxidative stress,
both constructs show presence in stress granules. BRF2:aa97-275 retains its
nuclear localization after arsenite treatment. BRF2:aa1-275, however, adopts a
strong cytoplasmic localization following stress. This behaviour of BRF2:aa1-
275 on arsenite treatment can be explained in the following ways. a) it interacts
with some factor which either masks the existing NLS or promotes passive
export out of the nucleus. b) it loses an interactor or changes its conformation
such that a second NES somewhere in the N-terminus is exposed. I scanned
the N-terminal region of BRF2 for any sequence which could fulfill the criteria
of an NES. Indeed there appears to be a sequence in the N-terminal which
contains multiple leucines, one of the characteristics of a NES (approximately
BRF2 aa5-25) [Figure 6.4]. If this sequence acts as a NES, BRF2:aa97-275
probably fails to exit the nucleus upon arsenite treatment because it lacks this
region. The nature of this export signal is worth further investigation because
it appears to be activated under conditions of oxidative stress.
The results obtained with truncated BRF2 protein are also intriguing since
both truncations show a strong nuclear localization and potently induce AMD.
To date, AMD has not been reported to take place in the nucleus. This could
mean that a) the negligible amount left in the cytoplasm is sufficient to promote
AMD, b) there is active nucleo-cytoplasmic shuttling and AMD nevertheless
takes place in the cytoplasm, and c) that AMD could actually also be nucleus-
associated.
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Figure 6.2: BRF2 truncation mutants show nuclear localization and co-localize
with P bodies and oxidative stress-induced stress granules. On exposure to
oxidative stress, BRF2:aa1-275 shifts to cytoplasm from the nucleus. Panel
A, B: HeLa cells were transfected with HA-BRF2 wildtype, HA-BRF2:aa1-275, or HA-
BRF2:aa97-275. Cells were stained with mouse monoclonal anti-HA antibody to visualise
BRF2 protein in samples in all the panels below. Panel A: Cells were co-stained for Rck
protein, a P body marker. Cells from the panel to the extreme right were exposed to
Leptomycin B (10 ng/ml, 2 hrs) prior to fixing and stained as above to visualize BRF2
protein. Panel B: Cells were exposed to oxidative stess (500 µM arsenite, 45 mins) prior
to fixing and co-stained for eIF3 protein, a marker for oxidative stress-induced stress
granules.
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Figure 6.3: Truncated mutants of BRF2 are capable of degrading ß-globin-
ARE reporter mRNA. A Tet-off system was employed. HeLa cells were transfected
with the empty-vector, or plasmids encoding HA-BRF2 wildtype, HA-BRF2:aa1-275, or
HA-BRF2:aa97-275 as indicated in the figure. doxycycline -chase mRNA decay assays
were performed over a period of 3 hrs. Northern blotting was carried out as mentioned
in Figure 3.7 legend. Panel C: Samples of transfected cells were processed by western
blotting and probed with mouse monoclonal anti-HA antibody to detect BRF2 protein
levels.
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Figure 6.4: Putative NES in N-terminus of BRF2. N-terminus of BRF2 was
scanned for presence of hydrophobic amino acids, especially Leucine, which optimally
constitute an NES. A putative NES in the N-terminus is highlighted in dark blue.
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7 Outlook and future directions
7.1 Summary
In my study, I performed experiments which led me to the following conclu-
sions:
1) BFR2 degrades mRNA in an ARE-dependent manner.
2) BRF2 binds to 14-3-3 in a phosphorylation-dependent manner. I studied
to greater detail the binding characteristics of BRF2 with 14-3-3 as a possible
means of regulation of the AMD activity of BRF2. I could establish that S123
and S257 together form the binding site for 14-3-3 on BRF2. This has been
similar to the 14-3-3 binding characteristics of TTP and BRF1 which have
been studied in detail before. There is a possibility that more than one species
of 14-3-3 interact with BRF2.
3) In analogy with TTP and BRF1, 14-3-3 binding to BRF2 was expected to
alter the AMD efficiency of BRF2. However, in my experiments performed so
far, it has been difficult to conclude anything to that effect. More experiments
are underway. BRF2-PP mutant behaved unlike the TTP-S54,180P mutant,
since instead of an expected increase in binding of BRF2-PP to 14-3-3, the
binding actually reduced.
4) Similar to BRF1 (and TTP regarding only MK2), MK2 and PKBA kinases
seemed to affect phosphorylation of BRF2 and 14-3-3 binding. 14-3-3 binding
appeared reduced when inactive forms of MK2 or PKBA kinases were co-
expressed along with BRF2. However, unlike observed in TTP and BRF1,
MK2 did not appear to alter AMD efficiency of BRF2 in the given experimental
conditions. This puts in question the role of MK2 with regard to modulating
the AMD efficiency of BRF2.
5) Nucleo-cytoplasmic localization, and co-localization to P bodies and to ox-
idative stress-induced stress granules was quantified for BRF2 wildtype, BRF2-
AA, and BRF2-PP. Both the 14-3-3 binding mutants showed a slightly more
nuclear presence than the BRF2 wildtype which remained predominantly cy-
toplasmic. On exposure to arsenite stress, a part of the nuclear fraction of the
BRF2 wildtype protein seemed to shift to the cytoplasm. All the three BRF2
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constructs spontaneously localized to P bodies equally efficiently, to arsenite-
induced stress granules with slightly varying efficiencies, and showed positive
nucleo-cytoplasmic shuttling.
6) In preliminary co-IP experiments, BRF2 interacted with Not1 (aa1300-
1601) and with Caf1a, indicating that BRF2 is associated with the mRNA
deadenylation machinery.
7) In preliminary experiments, BRF2:aa1-275 and BRF2:aa97-275 were seen to
localize to the nucleus. This could be because of lack of the NES present in the
C-terminal. Interestingly, BRF2:aa1-275 shifted to the cytoplasm on exposure
oxidative stress, which could indicate presence of an additional NES in the
N-terminal. Moreover, it was seen that the central RBD region consisting of
the two 14-3-3 sites and two zinc fingers was sufficient to promote AMD of
ß-globin-ARE reporter mRNA.
7.2 Future directions:
Second NES in BRF2 ?
A plasmid construct encoding BRF2:aa1-96 + NLS + GFP could be trans-
fected into the cells to check if the presence of BRF2:aa1-96 causes export of
the nuclear GFP. Additionally, the interactors to this portion could be studied
by mass spectrometry to know what contributes to export to cytoplasm on
oxidative stress.
Do different domains of BRF2 have different regulatory roles ?
A simplified view of the BRF2 partial [234] and complete [235] knockout mice
studies might indicate that BRF2:aa30-494 could be sufficient to bring about
hematopoiesis, while BRF2:aa1-29 could be necessary for fertility. This could
mean that different regions of BRF2 are involved in distinct functions and
could involve diverse sets of interacting partners depending on the stage of
life. Study of proteins interacting with individual domains of BRF2 by mass
spectrometry could possibly reveal the role of BRF2 in embryonic development
and possible housekeeping functions.
Is PKB involved in regulating BRF2 activity ? A future direction and a hy-
pothesis.
BRF2, on over-expression, triggered apoptosis in a p53-dependent manner
[242] and activated pro-apoptotic factors like caspase-3 and poly ADP-ribose
polymerase (PARP) [236]. Over-expressed BRF2 triggered an S-phase check-
point response in HeLa cells, and caused growth inhibition. Taken together,
this suggests that under favourable growth conditions, BRF2 could play a role
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in regulating cell cycle/growth. Incidentally, arsenite-induced oxidative stress
is known to result in mitotic arrest of the cells [264]. It could be possible that
such a cell-cycle arrest is achieved via BRF2. If so, then under conditions
of stress, functional BRF2 protein would be required to achieve the cell-cycle
arrest, and this could possibly justify why BRF2 may not be deactivated by a
stress-induced kinase like MK2. Moreover, ARE-binding proteins, e.g. HuR,
have already been implicated in effectuating hypoxic stress response [165, 166].
If BRF2 inhibits cell cycle progression, in favourable growth conditions when
growth is to be facilitated, BRF2 activity might have to be supressed possibly
via some kinase. PKB kinase could serve as an example of such a kinase. PKB
is known to phosphorylate and deactivate components of apoptotic machinery,
thus promoting survival. In conditions of DNA damage, PKB is deactivated
by binding to homodimers of 14-3-3 sigma, curbing its proliferative effect (re-
viewed in [265]).
For further studies, the effect of PKB on BRF2 could be examined. PKB
is a pro-proliferative kinase [266] and BRF2 is an anti-proliferative protein,
therefore seemingly opposite in function, and a fine balance needs to exist
between these pro- and anti-proliferative mechanisms for steady growth to
occur. In conclusion, it would be interesting to check whether PKB modulates
BRF2 activity, and viceversa. Probing deeper into these networks might expose
new targets for anti-cancer therapies.
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7.2 Future directions:
Acronyms
Acronym Expanded form
ADAR-1 adenosine deaminase acting on RNA-1
Ago Argonaute
AMD adenylate/uridylate-rich element-mediated
mRNA decay
AMP adenosine mono phosphate
ARE adenylate/uridylate-rich element
AUBP AU-rich element binding protein
BRF1 Butyrate response factor 1
Ccr4 catabolite repressor protein 4
co-IP co-immunoprecipitation
CTD C-terminal domain
Dcp decapping protein
DMEM Dulbecco’s modified eagle’s medium
ELAV embryonic-lethal abnormal vision
EMSA electrophoretic mobility shift assay
FACS fluorescence activated cell sorting
FCS fetal calf serum
FGF fibroblast growth factor
GFP green fluorescent protein
GM-CSF Granulocyte macrophage colony stimulating
factor
HA hemaglutinin
HDAC6 histone deacetylase 6
HSC hematopoietic stem cells
HuR human antigen R
IL interleukin
IRES internal ribosomal entry sites
JNK c-jun-N-terminal kinase
kDa kilo dalton
LPS lipopolysaccharide
MAPK mitogen-activated protein kinase
miRNA microRNA
MK2 MAPK-activated protein kinase-2
mRNP messenger ribonucleoprotein
NES nuclear export signal
NGD No-go mRNA decay
NLS nuclear localization signal
NMD Nonsense-mediated decay
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Acronym Expanded form
Not1 negative on TATA
NSD Nonstop mRNA decay
NTD N-terminal domain
P body processing body
PABP polyA binding protein
PAN polyAnuclease
PARN polyA ribonuclease
PARP and poly ADP-ribose polymerase
PCR polymerase chain reaction
PDGF platelet derived growth factor
PI-3 phosphoinositide-3
PKBA Protein kinase BA
polyA poly adenosine
PTC premature stop codon
RBD RNA-binding domain
RNA Ribonucleic acid
SG stress granule
TNFA Tumor necrosis factor A
TTP tristetraprolin
UTR untranslated regions
UV ultraviolet
VEGF vascular endothelial growth factor
VHL von Hippel Lindau protein
YFP yellow florescent protein
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Plasmid construction:
pcDNA3 was obtained from Invitrogen and pTet-off was obtained from Clonetech.
The construction of the following plasmids has been previously described:
pcDNA3-HA (p2003) and pcDNA-YFP (p2168) [67], pcDNA3-myc-MK2-EE
(p2064), pcDNA3-myc-MK2-K76R (p2065) [257], pcDNA3-7B (p2308), and
pTet-7B-ARE (p2260) [194], pCMV5-m/pPKBA (p2070) , and pCMV5- PKBA-
K179R (p2071) [211].
Plasmid pcDNA3-HA-BRF2 (p2114) was constructed by amplifying the coding
region of human BRF2 gene using human cDNA as template and primers
G1179 / G1034 and was cloned into the BamHI and XbaI sites of pcDNA3-
HA. The XbaI site in pcDNA3-HA-BRF2 (p2114) gets methylated due to the
formation of a GATC sequence at the XbaI site. This makes if resistant to
XbaI digestion. In primer G1390, an additional G was added between the gene
sequence and the XbaI restriction site to disrupt the GATC formation, thus
reviving the functionality of the XbaI site. BRF2 coding region from p2114
was amplified using primers G1389 / G1390 and the product was digested
with BamHI and XbaI and ligated into pcDNA3-YFP backbone digested with
BamHI and XbaI to generate pcDNA-YFP-BRF2 (p2769).
Site-directed mutagenesis was performed to create BRF2 phosphorylation-site
mutants, namely, pcDNA3-YFP-BRF2-S123A (p2727), pcDNA3-YFP-BRF2-
S257A (p2913), pcDNA3-YFP-BRF2-S492A (p2728), pcDNA3-YFP-BRF2-
S123,257A (p2870). DNA stretches 5’ and 3’ to the desired mutations were
amplified individually as two overlapping fragments, with the overlapping re-
gions containing the desired mutation. The following primers were used for
the same; primers G1389 / G1391 (5’ fragment) and G1392 / G1390 (3’ frag-
ment) for BRF2-S123A and primers G1389 / G1396 (5’ fragment) and G1397
/ G1390 (3’ fragment) for BRF2-S257A. The above 5’ and 3’ fragments were
aligned and were subjected to one more round of amplification using primers
G1389 and G1390 to yield full-length coding regions of BRF2 harbouring re-
spective mutations. Primers G1389 and mutation-containing G1395 were used
to construct pcDNA3-YFP-BRF2-S492A. The above products were then di-
gested with BamHI and XbaI and cloned into the same sites of pcDNA-YFP.
For creating pcDNA-YFP-BRF2-S123,257A double mutant, the 5’ region of
BRF2-S123A existing between BamHI and XhoI sites was swapped with the
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corresponding unmutated 5’ region of BRF2 in pcDNA-YFP-BRF2-S257A.
pcDNA-YFP-BRF2-S125,259P double mutant (p3080) was created using long
primers G2536 / G2637 wherein each primer harbours one desired mutation.
The PCR-amplified product was digested with restriction enzymes AflII and
XhoI and this product was swapped with the corresponding region of the
wildtype BRF2 from the plasmid pcDNA3-YFP-BRF2. The BRF2 coding
sequences corresponding to the two double mutants were excised from the
pcDNA-YFP backbones by digestion with BamHI and XbaI and subcloned into
the same sites of pcDNA3-HA to give pcDNA3-HA-BRF2-S123,257A (p2870)
and pcDNA-HA-BRF2-S125,259P (p3018).
pcDNA-HA-BRF2:aa1-275 (p3077) was generated by digesting pcDNA-YFP-
BRF2 (p2769) with enzymes BamHI and XhoI and was subcloned between the
same sites of pcDNA3-HA. To generate pcDNA-HA-BRF2:aa97-275, primers
G2693 / G2694 and pcDNA-YFP-BRF2 (p2769) as template were used, the
amplified product was digested with EcoRI and XbaI, and subsequently cloned
into the same sites of pcDNA3-HA.
The PCR program used to amplify full-length BRF2 is listed in Table 8.1. Du-
rations of the elongation step are modified depending on the length of expected
product.
Table 8.1: PCR program for amplification of full length BRF2. An-
nealing times reduced depending on the length of amplified product.
Temperature (oC) Duration (mins) Cycles
94 3 1
94 1
50 1 5
72 1.5
94 1
57 1 35
72 1.5
72 10 1
4
Cell culture and transfection:
The cell lines used in this study are listed in Table 8.2.
All cell lines used in this study are adherent cells and grow as monolayer
cultures. Cells lines were maintained at 37oC, 5% CO2, in Dulbecco’s modi-
fied Eagle’s medium (DMEM; Sigma) with additions of 10 % fetal calf serum
(FCS; Biochrom AG), 2mM L-Glutamine, 100 U/ml penicillin and 0.1 mg/ml
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Table 8.2: Cell lines used in this study.
Cell line Remarks
HEK293 Hypotriploid human embryonic kidney cell line (CRL-1573)
HeLa Human cervical epithelial adenocarcinoma cell line (CCL-2)
HT1080 Human connective tissue fibrosarcoma cell line (CCL-121)
HTwt16 Derivative of HT1080 cell line, stably expressing GFP-IL3 reporter
SlowC Derived by chemical mutagenesis of HTwt16, both alleles of BRF1 dysfunctional
SC-B1-1 SlowC stably expressing full-length HA-BRF1
SC-B1-2 SlowC stably transfected with, but not expressing HA-BRF1
SC-B2-1 SlowC stably expressing HA-BRF2 fragment
SC-B2-2 SlowC stably expressing HA-BRF2 fragment
SC-B2-3 SlowC stably transfected with, but not expressing HA-BRF2
SC-B2-4 SlowC stably expressing full-length HA-BRF2
SC-B2-5 SlowC stably expressing HA-BRF2 fragment
SC-B2-6 SlowC stably transfected with, but not expressing HA-BRF2
streptomycin (all from PAN biotech). Cells were trypsinized using trypsin-
EDTA (PAN biotech), and subcultivation ratio was 1:10 to 1:16 depending on
individual growth rates.
For transient transfections for co-immunoprecipitation experiments, DNA was
transfected using polyethylineimine (PEI; Polysciences Inc.) with a ratio of
DNA:PEI equalling 1: 2.5 in serum-free DMEM devoid of antibiotics. After 4
hrs of incubation, medium was changed to regular medium that included serum
and antibiotics. For immunoflorescence experiments, Fugene HD transfection
reagent (Promega) was used for transfections according to manufacturer’s pro-
tocol.
100 nM siRNAs were transfected using Lipofectamine 2000 twice over a period
of 5 days. Serum starvation treatment involved incubating cells with DMEM
containing 0.1 % FCS for indicated durations, arsenite treatment included ex-
posure of cells to 500 µM arsenite for 45 mins, anisomycin treatment included
exposure to 10 µg/ml anisomycin for 30 mins. Kinase inhibitors SB202190 and
wortmanin were used at working concentrations of 10µM and 15µM, respec-
tively, for a duration of 1 hr. Durations of treatments were calculated keeping
as reference the time of final lysis of cells for co-IP experiments or that of
commencement of RNA decay assays.
Stable transfections:
Htwt16 and SlowC cells were generated as mentioned in [227]. SlowC cell lines
were stably transfected with plasmids encoding HA-tagged versions of BRF1
or BRF2 after prior linearization of the plasmids with DraIII restriction en-
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zyme. 48 hrs after transfection, G418 (1 mg/ml) was added to the medium
to eliminate untransfected cells, and the remainder cells were allowed to grow
further till they formed visible colonies. Samples of cells were dislodged gently
from the centre of each selected transformant colony, aspirated directly from
the colony using a micropipette, while visualising under the microscope, and
inoculated into individual wells of a 24-well plate pre-containing 500 µl growth
medium per well. Each individual clone was expanded using growth medium
+ G418 drug and tested by FACS to guage the GFP signal intensity of the
clones. Positive clones were expected to have an increased AMD efficiency,
degrade GFP-IL3 mRNA more efficiently, leading to lower GFP protein signal
intensity lower, all of the above when compared to SlowC cells. All clones
showing reduced GFP signal intensity were expanded individually. One clone
per transfection was chosen in which the GFP signal intensity remained un-
changed, i.e. showed GFP signal intensity similar to SlowC cells; this clone
would serve as a negative control for later experiments.
Immunoprecipitation and Western blotting:
4 X 106 HEK293 cells were seeded per 10-cm dish, transfected the next day,
and incubated for 24 hrs before the time of lysis. Cells from each such dish were
lysed in 400 µl RNP lysis buffer (50 mM Tris-HCl ppH 8.0, 150 mM NaCl,
1 mM MgCl2, 1% NP-40, 10% glycerol, 1 mM DTT, Complete EDTA-free
protease inhibitor cocktail (Roche) and the following phosphatase inhibitors;
1mM NaVO3, 50 mM NaF, 40 nM Okadaic acid). For the phosphatase treated
samples, Lambda phage phosphatase (NEB) was included in the lysis buffer
at the concentration of 1 unit/µl and phosphatase inhibitors were excluded.
YFP-tagged proteins were purified as mentioned in [244]. GFP-binder beads
with protein complexes attached to them were washed 6 times with above
RNP lysis buffer, excluding phosphatase inhibitors, and later boiled with 2X
Laemmli buffer. Inputs and eluted complexes were resolved on 10% SDS-
polyacrylamide gels and transferred onto nitrocellulose membranes with pore-
size of 0.2 µM (Peqlab) for western blotting. The blots were developed using
Western Lightening chemiluminiscence substrate (Perkin Elmer) and medical
X-ray films (Fujifilm).
RNA decay assays and Northern blotting:
For RNA decay experiments using stable lines, 8 X 106 cells per cell line were
seeded on Day I. On Day II, cells were trypsinized and split into 4 equal aliquots
and were incubated with 5 µg/ml ActinomycinD for indicated time intervals.
11 µg of total RNA per sample was processed further. RNA probes to be used
were generated by PCR amplification using primers G293/G294 against IL3-I
and primers G078/G1008 against human RPS7 (loading control).
For RNA decay experiments using the Tet-off transient transfection system,
4 X 106 HeLa cells were seeded on Day I, transfected on Day II with pTet-
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off plasmid (Clonetech), pTet-7B-ARE (globin-ARE) reporter plasmid, and
the experimental plasmid DNA as indicated. On Day III, cells belonging to
each transfection were trypsinized and split into 5 equal aliquots. Cells from
one aliquot were subjected to western blotting to estimate level of protein
expression. The remainder 4 aliquots were incubated with 1 µg/ml doxycycline
(Sigma) for indicated time intervals. Following this, total RNA was isolated
using Genematrix RNA purification kit (Eurx. Roboklon). 7 µg of total RNA
per sample was processed further. RNA probes to be used were generated by
PCR amplification using primers G1000/G1001 against exons 1 and 2 of rabbit
ß-globin and primers G83/G1009 against human nucleolin (loading control).
In cases of both ActinomycinD- and doxycycline -chase assays, total RNA
was resolved by electrophoresis on 1.1% agarose/2% formaldehyde/ MOPS
gel. The thus-resolved RNA was blotted overnight in 8X saline-sodium cit-
rate (SSC) onto Hybond-N+ membranes (GE healthcare). Membranes were
hybridized overnight at 55oC and probed with aforementioned digoxygenin-
labelled RNA probes that were synthesized in vitro using SP6 polymerase
(Fermentas). Membranes with the blotted RNA were washed at 65oC twice
with 2X SSC/0.1 % SDS for 5 mins each and twice with 0.5X SSC/0.1 % SDS
for 20 mins each. Alkaline phosphatase-coupled anti-digoxygenin Fab frag-
ment and CDP-Star substrate (both from Roche) were used according to the
manufacturers protocol for the detection of the probes.
RT-qPCR:
cDNA was synthesized from 2 µg of total RNA by reverse transcription using
random hexamers (Fermantas) and Transcriptor reverse transcriptase (Roche).
The reaction mixture contained the following: 2µg total RNA, 4 µl 5X tran-
scription buffer (Promega), 2 µl 10 mM dNTPs (dATP, dTTP, dGTP, dCTP),
0.01 µg random hexamer primers, 0.5 µl RNase inhibitor (Promega), 10 U tran-
scriptor reverse transcriptase (Roche). Reaction mixture was incubated for 30
mins at 55oC for cDNA synthesis after which the enzyme was inactivated at
85oC for 5 mins. cDNA thus generated was diluted 1:5 using PCR-grade water.
Real-time PCRs were carried out using 2.5 µl diluted cDNA as a template and
200 nM target specific forward and reverse primers. The following primers
were used for the PCR reaction: G2057 / G2059 for BRF1-Set I, G 2058 / G
2060 for BRF1-Set II, G 2061 / G 2063 for BRF2-Set I, G2062 / G2064 for
BRF2-Set II, and G1576 / G1577 for human nucleolin as internal control. 10 µl
reactions were set using SYBR green Mastermix (Roche) and were processed
using a Lightcycler 480 (Roche). The quantitative real time PCR program was
as seen in Table 8.3
Immunoflorescence:
HeLa cells were seeded in wells of a 6-well plate and transfected with plas-
mid DNA. Transfection mix was substituted with regular medium after 4 hrs
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Table 8.3: Quantitative real time PCR program.
Program Target (oC) Acquisition mode Hold Ramp rate
Pre-Incubation 95 none 5 min 4.4
95 none 10 sec 4.4
Amplification 55 none 15 sec 2.5
72 single 25 sec 4.8
95 none 5 sec 4.8
Melting curve 60 none 1 min 2.5
97 single - 0.11
Cooling 40 none 10 sec 2
and cells were incubated further for 2 hrs. Cells from each well were then
trypsinized and split into 5-8 wells (depending on the cell density) of a 24-well
plate and allowed to grow overnight. Cells to be visualised for stress gran-
ules were treated with 500 µM arsenite for 45 mins. Leptomycin treatment
involved incubating cells with 10 ng/ml leptomycin for 2 hrs. Subsequently,
cells were fixed with 5% para formaldehyde (PFA) and then with 20% chilled
methanol. As per requirement, cells were stained with anti-HA antibody to
visualize over-expressed HA-BRF2, anti-Rck antibody to stain P bodies, anti-
eIF3 antibody to stain SGs. To quantify the cellular localization of BRF2
and its association with P bodies or SGs, 100 transfected cells were observed
under the microscope and localization of BRF2 was noted down. Three in-
dependent transfections were analyzed to calculate average percentages and
standard errors of the mean (s.e.m.).
Antibodies used in this study:
Sr.
No. Antibody Remark Dilution Company
A003
14-3-3 beta
(K-19)
(Lot # D1808)
polyclonal 1:1000 Santa Cruz sc-630
A007 c-myc (9E10) monoclonal 1:1000 Covance MMS-150P
A024 GFP (ab290) polyclonal 1:10000 Abcam ab290
A026 HA.11 monoclonal 1:1000
Covance Innovative
Antibodies MMS-101P
A029 HuR (3A2) monoclonal 1:1000 Santa Cruz sc-5261
A040 RCK (Dhh1) polyclonal 1:1000 bethyl A300-461A
A050 BRF1+2 polyclonal 1:1000 Ch.Moroni, Basel
A096
Phospho-PKBA
(Ser473)
monoclonal 1:1000
Cell
Signaling(NEB)#4051
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Sr.
No. Antibody Remark Dilution Company
A097 PKBA polyclonal 1:1000
Cell Signaling(NEB)
#9272
A102 eIF3eta polyclonal 1:1000 Santa Cruz sc-16377
A134 MAPKAPK-2 polyclonal 1:1000
Cell Signaling(NEB)
#3042
A135
Phospho-
MAPKAPK-2
(Thr334)
polyclonal 1:1000
Cell SignallingNEB)
#3041
Secondary
antibodies:
donkey
anti-mouse IgG
HRP-
coupled
1:5000 Jackson ImmunoResearch
donkey
anti-rabbit IgG
HRP-
coupled
1:5000 Jackson ImmunoResearch
Cy2 donkey
anti-mouse
1:1000 Jackson ImmunoResearch
Cy3 donkey
anti-goat
1:1000 Jackson ImmunoResearch
Cy2 donkey
anti-rabbit
1:1000 Jackson ImmunoResearch
DNA oligonucleotides:
Name: DNA oligonucleotide sequence:
G 83 TTACAAAGTCACTCAGGATG
G 1000 GTGCATCTGTCCAGTG
G 1001 GCCGATTTAGGTGACACTATAGAAT
ACCCTGAAGTTCTC
G 1009 GCCGATTTAGGTGACACTATAGAAT
ACTTAGCGTCTTCG
G 1034 AATTCTCGAGGTTCTCCTTGTTG
G 1179 ATATGGATCCCCCTCCTGCTCTTC
G 1389 ATATGGATCCTCGACCACACTT
G 1390 ATATTCTAGAGTCAGTCGTCGGA
G 1391 CAAATTCCGGGACCGCGCGTTTAGCGAG
G 1392 CTCGCTAAACGCGCGGTCCCGGAATTTG
G 1395 CGCCTGTCCGACGCGCCCGTGTTCGAC
G 1396 GTCGAACACGGGCGCGTCGGACAGGCG
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Name: DNA oligonucleotide sequence:
G 1397 ATATTCTAGAGTCAGTCGTCGGCGATGGAGAGGC
G 1576 GTTGCACCACGCCCTCAGCTTC
G 1577 GAAGCTGAGGGCGTGGTGCAAC
G 2057 GTCTGCCACCATCTTCGAC
G 2058 CCACCATCTTCGACTTGAGC
G 2059 GGGCAGGGTGACTGAGTG
G 2060 CTGGGCAGGGTGACTGAG
G 2061 TTCTGTCCGCCTTCTACGATG
G 2062 CTGTCCGCCTTCTACGATGTC
G 2063 GAGTGCCGTCGGAGGAATC
G 2064 AGTGCCGTCGGAGGAATC
G 2536 CCCTTAAGGAGCCGTCGGGGGGCGGCGGCACA
GCCCTGCTCAACAAGGAGAACAAATTCCGGGA
CCGCTCGTTTCCGGAGAACGGCGAT
G 2537 CGACTCGAGGCCGCCCGGGGGCTGATGGTGGC
CCGACGGGAAGCCCGAGAACGGGAGGCTGTGGTG
G 2693 CAGTGAATCCCCTACGGCACCCTTAAGG
G 2694 CAGTAGATCTCGGGCGAGTCGGACAGGC
Northern probes:
Sr. No. Oligonucleotide sequence Remark
G1000 GTGCATCTGTCCAGTG Bex12 probe_forward
G1001 GCCGATTTAGGTGACACTAT
AGAATACCCTGAAGTTCTC
Bex12 probe
Sp6_reverse
G083 TTACAAAGTCACTCAGGATG hNCL probe_forward
G1009 GCCGATTTAGGTGACACTATA
GAATACTTAGCGTCTTCG
hNCL probe
SP6_reverse
G293 AACAGCAGGCAGAGCAC IL3-I probe_forward
G294 GCCGATTTAGGTGACACTAT
AGAATACAGGAACATAATTAG
Sp6-IL3-I
probe_reverse
G078 GGTGGTCGGAAAGCTATC hRPS7 probe_forward
G1008 GCCGATTTAGGTGACACTAT
AGAATACTATAGACACCAG
hRPS7 probe
SP6_reverse
siRNAs used in this study:
Sr.No. siRNA Sequence
S002 D0 (Non-specific) GCAUUCACUUGGAUAGUAA
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Sr.No. siRNA Sequence
S057 siRNA-MK2 UCACCGAGUUUAUGAACCA
Disposable materials and kits:
Material / Kit Company
1.5 ml, 2 ml Reaction Tubes Eppendorf
15 ml, 50 ml Falcon Tubes Falcon, Greiner, Nunc
2 ml Cryotubes Nunc
Filter tips StarLab
Filter paper Whatman 3MM Whatman
Cellscraper CoStar Corning Inc.
CellStar Tissue culture flasks (T75, T25) Greiner Bio-One
CellStar Tissue culture dishes (6, 10,
15cm)
Greiner Bio-One
CellStar Cell culture plates (6-well,
12-well, 24-well)
Greiner Bio-One
DIG labelling Kit Ambion
Gloves Meditrade
Pipette tips Steinbrenner, Starlab
PureLink HiPure Plasmid Midiprep Kit Invitrogen
PureLink HiPure Plasmid Maxiprep Kit Invitrogen
QIAquick Gel Extraction Kit QIAgen
QIAprep Spin Miniprep Kit QIAgen
QIAquick PCR Purification Kit QIAgen
QIAquick Nucleotide Removal Kit QIAgen
Rapid DNA Ligation Kit Fermentas
RNA Isolation Kit EURx, Roboklon
Transcriptor First Strand cDNA
Synthesis Kit
Roche
Chemicals used in this study:
Chemical Company
10x Taq Polymerase Buffer QIAgen
2-Mercaptoethanol (2-ME) Sigma
5x Transcription Buffer Promega
Acetic Acid Fluka
Actinomycin D AppliChem
Agarose Biozym Scientific GmbH
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Chemical Company
Ammoniumpersulfate AppliChem
Ampicillin Applichem
Bromphenol blue Applichem
Calf Intestine Phosphatase (CIP) New England Biolabs
Chloroform VWR
Complete Protease Inhibitor Cocktail
Tablets, EDTA-free
Roche
Coomassie Brillant Blue R250 ROTH
Coomassie Brillant Blue R250 AppliChem
Desoxyadenosine triphosphate (dATP) Fermentas
Desoxycytidine triphosphate (dCTP) Fermentas
Desoxyguanosine triphosphate (dGTP) Fermentas
Desoxythymidine triphosphate (dTTP) Fermentas
DH5alpha competent E. coli cells Invitrogen
DIG labelling mix Roche
Dimethylsulfoxid (DMSO) Serva Electrophoresis
Disodiumhydrogenphosphate Roth
Dithiothreitol (DTT) Applichem
doxycycline e AppliChem
Ethanol Riedel-de-Haen
Ethidium bromide (EtBr) Applichem
Ethylenediaminetetraacetic acid (EDTA) Roth
Formaldehyde Merck
Formamide AppliChem
Gene Ruler 1kb Ladder Plus Fermentas
Glycerol Roth
Glycine Gerbu
HEPES Roth
Isopropanol Sigma-Aldrich
Kanamycinesulfate Roth
L-glutamine PAN
Lipofectamine 2000 Invitrogen
Magnesium chloride Merck
Maleic acid Fluka
Methanol Fluka
Milk powder Roth
MOPS Roth
Nonidet P-40 (NP-40) US Biological
O’GeneRuler 100bp Plus DNA Ladder Fermentas
Ocadaic acid Sigma-Aldrich
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Chemical Company
PageRuler Prestained Protein Ladder Fermentas
Paraformaldehyde AppliChem
Penicillin-streptomycin PAN
Polyethyleneimine (PEI) Polysciences Europe
Ponceau S MD
Potassiumacetate Roth
Potassiumchloride Roth
Random hexamers Fermentas
Restriction Enzymes New England Biolabs
RNase inhibitor RNasin Promega
Rotiphorese Acrylamide Solution Roth
RQ1 DNase Promega
Sodium arsenite Fluka
Sodium azide AppliChem
Sodium chloride Sigma-Aldrich
Sodium dodecyl sulphate (SDS) Gerbu
Sodium hydroxide pellets Riedel-de-Haen
Sodiumfluoride Sigma-Aldrich
Sodiumvanadate Sigma-Aldrich
SP6 polymerase Fermentas
T4 DNA Ligase Fermentas
TEMED AppliChem
Thermo polymerase buffer New England Biolabs
Transcriptor reverse transcriptase Roche
Transcriptor reverse transcriptase 5x reaction
buffer
Roche
Trisodiumcitrate VWR
Triton-X-100 Applichem
Trizma base Sigma-Aldrich
Trypsin/EDTA PAN
Tween-20 Sigma-Aldrich
Vent DNA Polymerase New England Biolabs
Xylenecyanol Applichem
Yeast tRNA Ambion
Equipment:
Equipment / instrumentation Company
Freezer -20°C Liebherr
Freezer -80°C x Liebherr
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Equipment / instrumentation Company
Fridge 4°C Liebherr
Cell Culture Incubator Hera cell
Centrifuge (5417R) Eppendorf
Centrifuge (J2-MC, rotor JA-17) Beckman
Centrifuge (Labofuge M) Heraeus Sepatech
Centrifuge (Multifuge 1S) Thermo
Centrifuge (Pico17) Thermo
Film Development Apparatus
(HyperProcessor)
Amersham
GeneAmp PCR System 9700 Applied Biosystems
Heating Block (neoBlock 1) NeoLab
Intelli-mixer NeoLab
Laminar Flow Cabinet Hera cell
Magnetic Stirrer (MR3001) NeoLab
Micropipettes Gilson
Microwave Privileg
Mini Protean 3 Cell BIORAD
Mini Trans Blot Cell BIORAD
Nanodrop ND 1000 PeQLab
pH Meter (766 Calimetic) Knick
Poly-Prep column Biorad
Power Supply (powerpack300) Biorad
Scale (440-47N) Kern
Shaker (DOS-20S) NeoLab
Shaker (PMR-30) Grant-bio
Sorvall Discovery 90SE Thermo Scientific
Speedvac Eppendorf Concentrator
TurboBlotter (northern blotting) Whatman
UV Gel Documentation System Raytest IDA
UV Table (TVL-312A) Specktroline
Vortex NeoLab
Waterbath GFL
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